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Photoredox-catalyzed	procedure	for	carbamoyl	radical	generation:	
3,4-dihydroquinolin-2-one	and	quinolin-2-one	synthesis	
Wade	F.	Petersen,	Richard	J.	K.	Taylor	and	James	R.	Donald
*	
A	reductive	approach	for	carbamoyl	radical	generation	from	N-hydroxyphthalimido	oxamides	under	photoredox	catalysis	
is	 outlined.	 This	 strategy	 was	 applied	 to	 the	 synthesis	 of	 3,4-dihydroquinolin-2-ones	 via	 the	 intermolecular	
addition/cyclization	of	carbamoyl	radicals	with	electron	deficient	olefins	in	a	mild,	redox-neutral	manner.	Under	a	general	
set	of	reaction	conditions,	diversely	substituted	3,4-dihydroquinolin-2-ones,	including	spirocyclic	systems	can	be	prepared.	
By	using	chlorine-substituted	olefins,	aromatic	quinolin-2-ones	can	also	be	accessed.	
Introduction	
The	 growing	 application	 of	 photoredox	 catalysis	 in	 organic	
synthesis	within	the	last	decade	has	enabled	the	development	
of	 milder	 and	 less	 toxic	 alternatives	 to	 traditional	 radical	
chemistry	 and	 perhaps	 more	 importantly,	 facilitated	 the	
invention	 of	 entirely	 new,	 hitherto	 unattainable	 reactivity	
modes,	made	possible	by	the	continual	generation	of	strongly	
oxidizing	 and	 reducing	 species	 within	 the	 same	 pot.
1
	 Visible	
light	 photoexcitation	 of	 metal	 polypyridyl	 complexes	 or	
organic	 dyes	 at	 wavelengths	 to	 which	 common	 organic	
molecules	 are	 transparent	 generates	 excited-state	 species	
capable	of	selective	radical	formation	in	reaction	substrates	via	
single-electron	 transfer	 (SET)	processes,	 thus	 triggering	open-
shell	 reactivity	 and	 initiating	 chemistry.	 Redox-neutral	
transformations	 are	 particularly	 desirable,	 removing	 the	
requirement	 for	 stoichiometric	 chemical	 oxidants	 or	
reductants,	and	by	virtue	of	an	 ‘electron	borrowing’	 strategy,	
such	 processes	 occupy	 reactivity	 space	 complementary	 to	
electrochemistry.	
Carbamoyl	 radicals	1	 are	 versatile	 reactive	 intermediates,	
which	 generally	 display	 improved	 stability	 over	 their	 more	
heavily	 studied	 acyl	 and	oxycarbonyl	 counterparts	 (which	 are	
prone	 to	 decarbonylation	 and	 decarboxylation,	 respectively),	
making	 them	 ideally	 suited	 to	 the	 synthesis	 of	 amide-
containing	compounds.
2
	Major	areas	of	application	are	Minisci		
chemistry,
3
	 intermolecular	 alkene/alkyne	 addition
4,5
	 and	
intramolecular	 cyclization	 to	 form	 lactams	 (Scheme	 1),
3b,4g,6
	
while	 other	 uses	 include	 C–H	 abstraction	 to	 produce	
formamides,
6n,7
	 oxidation	 to	 isocyanates,
3b
	 addition	 to	 azo	
compounds,
8
	 alkynylation,
9
	 and	 in	 Pd-catalyzed	 processes,	
both	as	a	coupling	partner
10a
	and	as	a	carboxylate	source.
10b
	
The	 generation	 of	 carbamoyl	 radicals	 however,	 has	 been	
historically	 limited	to	two	general	strategies.	These	are	(i)	 the	
use	of	classical	radical	chemistry,	via	homolytic	C−X	cleavage
11
	
of	a	suitably	functionalized	acyl	precursor	 induced	by	either	a	
radical	 initiator,	 heat,	 or	UV	 light	 (Scheme	 1A)
3c,d,4a–h,5,6a–q,s,7,8
	
and	 (ii)	 oxidative	 approaches	 via	 electron	 transfer	 from	 α-
amidocarboxylates	 to	 stoichiometric	 single-electron	 chemical	
oxidants	with	subsequent	loss	of	CO2,	usually	conducted	at		
Scheme	1	Generation	and	application	of	carbamoyl	radicals.	
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elevated	temperatures	(Scheme	1B).
3a,b,4i,j,9,10
	
We	 proposed	 that	 a	 reductive	 approach	 to	 carbamoyl	
radicals	 might	 provide	 a	 basis	 for	 the	 development	 of	
chemistry	not	possible	under	existing	modes	of	generation,	 in	
particular	 offering	 the	 possibility	 of	 overall	 redox-neutral	
transformations	 for	processes	 terminated	by	an	oxidative	SET	
event.	 To	 this	 end,	we	 recently	 reported
12
	 the	 first	 reductive	
approach	 to	 carbamoyl	 radicals	 from	 N-hydroxyphthalimido	
oxamides,
13,14
	mediated	under	mild	conditions	by	photoredox	
catalysis.	 The	 value	 of	 the	 strategy	 was	 demonstrated	 via	
trapping	 the	 intermediate	 carbamoyl	 radicals	 with	 electron	
deficient	 olefins	 in	 an	 intermolecular	 addition/cyclization	 to	
achieve	 a	 redox-neutral	 synthesis	 of	 3,4-dihydroquinolin-2-
ones	(Scheme	1C).	In	this	publication,	we	disclose	full	details	of	
the	 reaction	 development,	 further	 probe	 the	 scope	 of	 the	
process,	 particularly	 in	 terms	 of	 aryl	 substituted	 radical	
acceptors	and	spirocycle	formation	and	introduce	an	extension	
of	the	original	approach	to	target	the	aromatic	quinolin-2-one	
core	under	our	standard	reaction	conditions.	
The	 3,4-dihydroquinolin-2-one	 bicyclic	 system	 comprises	
the	 core	 of	 several	 natural	 product	 families,	 representative	
examples	 include	 insecticidal	 yaequinolone	 E	 (2),
15
	 fused-	
spirocyclic	 (+)-meloscine	 (3)
16
	 and	 spirocyclic	
acetylcholinesterase	 inhibitor	 trigolutesin	 A	 (4)	 (Figure	 1).
17
	
Notable	synthetic	3,4-dihydroquinolin-2-ones	are	compound	5	
which	 is	an	activator	of	 the	 tumor	cell	 specific	M2	 isoform	of	
pyruvate	 kinase,
18
	 the	HIV	 reverse	 transcriptase	 inhibitor	 and	
efavirenz	 analogue	 (6)
19
	 and	 the	 partial	 dopamine	 agonist	
aripiprazole	 (7)	 which	 is	 one	 of	 the	 top	 selling	 US	
pharmaceuticals,	 used	 to	 treat	 a	 range	of	mental	disorders.
20
	
Figure	1	3,4-Dihydroquinolin-2-ones	and	quinolin-2-ones	of	medicinal	interest.	
Aromatic	 quinolin-2-ones	 are	 also	 frequently	 found	 in	
bioactive	 molecules	 and	 present	 an	 attractive	 core	 for	
pharmaceutical	 development.
21
	 Illustrative	 examples	 are	 the	
potent	anti-inflammatory	natural	product	N-methylflindersine	
(8),
22
	the	synthetic	selective	androgen	receptor	modulator	LGD	
2226	 (9)
23
	 and	 compound	 10,	 derived	 from	 parent	 natural	
product	N-methylquinolin-2-one
24
	and	optimized	for	inhibition	
of	 the	 bromodomain	 of	 bromodomain	 and	 PHD	 Finger-
Containing	(BRPF)	proteins.
25
	
Consequently,	 we	 selected	 the	 synthesis	 of	 3,4-
dihydroquinolin-2-ones	 as	 the	 proving	 ground	 for	 our	 novel	
reductive	 carbamoyl	 radical	 generation	 in	 the	 hope	 of	
producing	 a	 diverse	 library	 of	 heterocyclic	 structures,	 in	 line	
with	our	program	to	develop	new	strategies	 for	 the	synthesis	
of	 medicinally	 relevant	 nitrogen-containing	 ring	 systems.
26–29
	
Additionally,	 we	 also	 sought	 to	 access	 quinolin-2-ones,	 given	
their	value	to	the	biomedical	arena.	
Results	and	discussion	
After	 some	 experimentation,	 a	 general	 route	 to	 access	 the	
requisite	N-hydroxyphthalimido	oxamide	radical	precursors	on	
gram-scale	 was	 developed,	 via	 the	 acylation	 of	 anilines	 with	
chloro	N-phthalimidoyl	oxalate,	readily	prepared	by	Overman’s	
method,
30
	 followed	 by	 successive	 aqueous	 washings	 with	
dilute	 aq.	 HCl	 and	 then	 saturated	 aq.	 NaHCO3	 to	 remove	
residual	 pyridine/anilines	 and	 N-hydroxyphthalimide	
respectively	 (see	 Experimental	 section).	 The	 resulting	
oxamides	 were	 found	 to	 be	 unstable	 to	 silica	 gel	 column	
chromatography,	 but	were	 easily	 purified	 by	 recrystallization	
to	afford	bench-stable	crystalline	solids,	which	were	stored	in	
the	dark	as	a	precaution.	
The	addition-cyclization	process	was	first	evaluated	for	the	
formation	 of	 3,4-dihydroquinolin-2-one	 14	 using	 oxamide	 11	
(derived	 from	N-methylaniline)	 and	 ethyl	 acrylate	 (12)	 (Table	
1).	With	2	mol%	Ru(bpy)3.6H2O	in	MeCN,	after	24	h	irradiation	
with	blue	LEDs,	we	were	pleased	to	observe	the	formation	of	
the	desired	product	14	 in	 19%	 yield	 (determined	by	
1
H	NMR	
spectroscopy	 with	 an	 internal	 standard,	 entry	 1).	 Increasing	
the	 loading	 of	 the	 commercial	 acrylate	 12	 led	 to	 a	 slight	
improvement	in	yield	at	2	eq.,	but	further	excess	was	found	to	
be	detrimental	(entries	2	and	3).	The	inclusion	of	i-Pr2NEt	(1.0	
eq.)	in	order	to	facilitate	a	reductive	quenching	cycle	was	non-
beneficial	(entry	4).	Variation	of	the	photocatalyst	significantly	
influenced	 reaction	 efficiency,	 with	 fac-Ir(ppy)3	 found	 to	 be	
superior	to	both	Ru(bpy)3.6H2O	and	eosin	Y,	 leading	to	a	27%	
yield	(entries	5	and	6).	Next,	from	a	screen	of	solvents,	toluene	
was	 found	 to	 be	 most	 suitable,	 affording	 lactam	 14	 in	 37%	
yield	(see	entries	7–9).	We	investigated	irradiation	with	a	30	W	
white	 compact	 fluorescent	 lamp	 (CFL)	 rather	 than	 the	 60	W	
blue	 LEDs	 but	 these	 conditions	 were	 found	 to	 be	 inferior	
(entry	 10).	 Finally,	 the	 effect	 of	 concentration	 was	 explored	
and	 higher	 dilution	 (0.04	 M)	 was	 determined	 to	 be	 optimal	
(48%	yield	by	
1
H	NMR	analysis),	affording	a	43%	isolated	yield	
of	3,4-dihydroquinolin-2-one	14	(entries	9,	11–13).	Control	
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Table	1	Reaction	Optimization.	
entry	 11:12/13
a	
photocat.	
(2	mol%)	
solvent	(M)	 yield	(%)
b
	
1
c
	 1:1	(12)	 Ru(bpy)3Cl2.
d
	 MeCN	(0.12)	 19%	
2
c
	 1:2	(12)	 Ru(bpy)3Cl2.
d
	 MeCN	(0.12)	 25%	
3
c
	 1:5	(12)	 Ru(bpy)3Cl2.
d
	 MeCN	(0.12)	 12%	
4
c,e
	 1:1	(12)	 Ru(bpy)3Cl2.
d
	 MeCN	(0.12)	 7%	
5
c
	 1:1	(12)	 fac-Ir(ppy)3	 MeCN	(0.12)	 27%	
6
c
	 1:1	(12)	 Eosin	Y	 MeCN	(0.12)	 13%	
7
c
	 1:1.5	(12)	 fac-Ir(ppy)3	 CH2Cl2	(0.12)	 26%	
8
c
	 1:1.5	(12)	 fac-Ir(ppy)3	 THF	(0.12)	 17%	
9
c
	 1:1.5	(12)	 fac-Ir(ppy)3	 PhMe	(0.12)	 37%	
10
f
	 1:1.5	(12)	 fac-Ir(ppy)3	 PhMe	(0.12)	 11%	
11
c
	 1:1.5	(12)	 fac-Ir(ppy)3	 PhMe	(0.24)	 25%	
12
c
	 1:1.5	(12)	 fac-Ir(ppy)3	 PhMe	(0.04)	 48%,	43%
g
	
13
c
	 1:1.5	(12)	 fac-Ir(ppy)3	 PhMe	(0.02)	 49%	
14
c
	 1:1.5	(12)	 –	 PhMe	(0.04)	 0%	
15
h
	 1:1.5	(12)	 fac-Ir(ppy)3	 PhMe	(0.04)	 0%	
16
c
	 1:1.5	(13)	 fac-Ir(ppy)3	 PhMe	(0.04)	 70%
g
	
aReaction	 Stoichiometry.	 bDetermined	 by	 1H	 NMR	 spectroscopy	 against	 an	
internal	standard	(BnOAc).	cIrradiated	with	60	W	blue	LEDs	and	fan	cooling	for	24	
h.	 dHexahydrate.	 eWith	 i-Pr2NEt	 (1.0	 eq.).	
fIrradiated	 with	 a	 30	 W	 white	 CFL.	
gIsolated	yield.	hReaction	conducted	in	the	dark.	
experiments	revealed	that	no	product	formation	was	observed	
either	 in	the	absence	of	photocatalyst	or	 light	(entries	14	and	
15).	 Knowing	 that	 ethyl	 acrylate	 (12)	 might	 be	 a	 particularly	
challenging	 reaction	 partner,	 we	 applied	 the	 reaction	
conditions	 to	 methyl	 methacrylate	 (13),	 an	 acceptor	
anticipated	 to	 better	 stabilize	 the	 intermediate	 conjugate	
radical	 and	 have	 a	 lower	 propensity	 towards	 undesired	
oligomerization	 reactions.	 Gratifyingly,	 in	 this	 case	 3,4-
dihydroquinolin-2-one	15	was	isolated	in	70%	yield	(entry	16).	
With	the	aforementioned	exciting	results	in	hand,	we	were	
now	 ready	 to	 explore	 the	 scope	 of	 our	 optimized	 conditions	
across	a	 range	of	 radical	acceptors	 (Scheme	2).	 In	addition	to	
3,4-dihydroquinolin-2-one	15,	a	second	quaternary	substituted	
example	16	bearing	a	phosphonate	ester	was	obtained	in	good	
yield.	 Mono-substituted,	 electron-deficient	 alkenes	 were	
found	 to	 be	 well	 tolerated	 in	 this	 reaction,	 offering	 3,4-
dihydroquinolin-2-ones	14	and	17–20	with	pendent	alkyl	ester,	
active	 ester,	 sulfone,	 ketone	 and	 nitrile	 groups	 in	 43–81%	
yield.	 The	 yield	 of	 the	 reaction	 was	 observed	 to	 mirror	 the	
electron-withdrawing	 and	 radical	 stabilizing	 nature	 of	 the	
alkene	 substituent.	 In	 contrast,	 no	 product	 formation	 (21	 or	
22)	was	observed	when	the	more	electon-rich	butyl	vinyl	ether	
or	 triethoxyvinylsilane	 were	 employed.	 This	 reactivity	 is	 very	
much	 in	 line	 with	 the	 nucleophilic	 character	 displayed	 by	
carbamoyl	radicals.
4b,31
	
cis-Fused	cyclopentanes	23	and	24	were	isolated	in	modest	
yields	under	our	general	set	of	conditions,	as	single		
Scheme	2	Radical	acceptor	scope.	
diastereomers,	 resulting	 from	 the	 attack	 on	 cyclopentenes	
bearing	 exo-	 and	 endocyclic	 electron-withdrawing	 groups	
respectively.	 The	 anticipated	 cis-fusion	 of	 cyclopentanone	 24	
was	 evidenced	 by	 an	 NOE	 correlation	 between	 the	 methyl	
group	and	 the	proton	at	 the	 ring	 junction.	Not	only	do	 these	
examples	 indicate	 that	 β-substitution	 is	 possible	 in	 this	
chemistry	but	 they	 also	 contain	 the	 [6,6,5]-core	of	meloscine	
(3)	 and	 many	 of	 the	 other	 melodinus	 alkaloids,	 with	 useful	
handles	for	further	synthetic	manipulation.	
	 Finally,	 we	 were	 interested	 to	 evaluate	 styrenyl-type	
olefins	as	 radical	acceptors.	Under	 the	 reaction	conditions,	4-
cyano-styrene	 afforded	 a	 complex	 mixture	 of	 products,	
possibly	 due	 to	 competing	 oligomer	 and	 polymer	 forming	
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reactions.	 Pleasingly	 however,	 when	 2-vinylpyridine	 was	
employed	 as	 the	 radical	 acceptor,	 2-pyridyl-3,4-
dihydroquinolin-2-one	 26	 was	 obtained,	 albeit	 in	 moderate	
yield.	 In	 the	 case	 of	 1,1-diphenylethylene,	 with	 two	 aryl	
substituents	 on	 the	 alkene	 input,	 cyclization	 of	 the	
intermediate	 conjugate	 radical	 did	 not	 occur,	 likely	 due	 to	
reduced	 electrophilicity	 and	 increased	 stability.	 Instead,	 the	
doubly	 benzylic	 radical	 appears	 to	 have	 undergone	 single-
electron	 oxidation	 and	 deprotonation	 to	 afford	 linear	 α,β-
unsaturated	amide	27.	
The	 oxamide	 inputs	 were	 then	 investigated	 in	 terms	 of	
scope	using	 the	 radical	 acceptor	methyl	methacrylate	 (13)	 as	
the	fixed	variable.	Five	p-substituted	N-methyl	oxamides	were	
subjected	 to	 the	 standard	 reaction	 conditions,	 affording	 3,4-
dihydroquinolin-2-ones	 28−32	 in	 38−80%	 unoptimized	 yield	
with	 a	 range	 of	 electron-withdrawing	 and	 electron-donating	
substituents.	Together	with	compound	15,	this	series	shows	a	
distinct	 correlation	 of	 increasing	 yield	 with	 increasingly	
electron-withdrawing	substituents	on	the	oxamides.	
Interestingly,	 the	m-methyl	 substituted	 oxamide	 afforded	
lactam	33	in	66%	yield	as	a	single	regioisomer,	owing	to	steric	
directing	effects.	In	contrast,	none	of	the	desired	3,4-		
Scheme	3	Oxamide	scope.	
dihydroquinolin-2-one	 34	 was	 observed	 when	 the	 o-methyl	
substituted	oxamide	was	subjected	to	the	process,	possibly	as	
a	consequence	of	the	non-planarity	of	the	o-substituted	anilide	
or	 due	 to	 undesired	 side	 reactions	 such	 as	 intramolecular	
benzylic	 C–H	 abstraction.
32
	 Pleasingly,	 the	 smaller	 and	 more	
electron-withdrawing	 o-fluoro	 substituent	 was	 compatible	
with	 the	 methodology,	 providing	 the	 8-fluoro-3,4-
dihydroquinolin-2-one	 35	 in	 41%	 yield.	 This	 result	 offers	
potential	 access	 to	 further	 o-substituted	 derivatives	 as	 aryl	
fluorides	present	a	useful	functional	handle	through	transition-
metal	catalyzed	cross-coupling	reactions.
33
	
N-Benzyl	and	N-allyl	3,4-dihydroquinolin-2-ones	36	and	37	
were	 isolated	 in	 54%	 and	 45%	 yields,	 respectively.	 These	
results	are	useful	as	the	products	bear	removable	N-protecting	
groups	 and	 noteworthy	 because	 the	 potential	 competing	
intramolecular	 cyclization	 of	 the	 carbamoyl	 radicals	 onto	 the	
pendant	N-benzyl
3b,6m,6q
	 and	N-allyl	 groups,
4g,6d,6g,6h,6l
	was	 not	
observed	 in	 this	work,	but	has	been	previously	demonstrated	
in	 the	 literature.	 Unfortunately,	 no	 product	 formation	 was	
detected	 when	 an	 oxamide	 bearing	 an	 electron-withdrawing	
N-Boc	substituent	was	used.	
The	Taylor	group	has	a	particular	 interest	 in	 the	synthesis	
of	 spirocyclic	 natural	 products	 and	 spirocyclic	 scaffolds	 with	
which	 to	 explore	 chemical	 space.
26a–e,27a,c
	 Taking	 inspiration	
from	 the	 spirocyclic	 natural	 products	 (+)-meloscine	 (3)	 and	
trigolutesin	A	(4),	we	targeted	spirocyclic	3,4-dihydroquinolin-
2-ones	 through	 the	use	of	 radical	acceptors	bearing	exocyclic	
alkenes.	 Pleasingly,	 the	 reaction	 of	 α-methylene-γ-
butyrolactone	 with	 a	 range	 of	 oxamides	 produced	 a	 small	
library	of	spirocyclic	 lactone-lactam	systems	39–43	 in	43–71%	
yield	 (Scheme	 4).	 Notably,	 in	 the	 case	 of	 the	 m-methoxy	
oxamide,	 the	 corresponding	 spirocycle	 was	 produced	 as	 a	
mixture	of	two	inseparable	o-	and	m-regioisomers	43a	and	43b	
in	 a	 ratio	 of	 1.00:0.56	 respectively	 (43%	 combined	 yield).	
Interestingly,	in	this	instance,	steric	effects	seem	to	play	a	less	
significant	 role	 in	 controlling	 the	 regioselectivity,	with	 orbital	
coefficients	 apparently	 dominating	 the	 position	 of	 aromatic	
substitution.	 It	 is	 anticipated	 that	 electronic	 and	 steric	
modification	of	the	group	on	the	phenolic	oxygen	atom	might	
offer	a	means	 to	 favor	 formation	of	 the	regioisomer	required	
for	a	synthesis	of	trigolutesin	A	(4).		
When	3-methylidene-1-phenylpyrrolidin-2-one	was	used	to	
trap	 the	 carbamoyl	 radical	 intermediates,	 spirorocyclic	
bislactams	44–46	were	produced	in	49–61%	yield.	Whilst	there	
are	 single-example	 publications	 featuring	 the	 synthesis	 of	
similarly	 structured	 gem-difluoro	 cyclic	 imide/gem-difluoro	
lactone	 and	 oxindole-	 3,4-dihydroquinolin-2-ones,	 a	 general	
method	for	the	preparation	of	the	simple	parent	systems	and	
exploration	of	biological	activity	has	not	been	reported.
34
	
Spirocyclic	 cycloalkanone-lactam	 ring	 systems	 can	 also	 be	
accessed	via	this	strategy	as	illustrated	by	the	formation	of	the	
spirocyclic	 [6,6]-product	47	 in	 60%	 yield.	 As	 an	 example	 of	 a	
more	complex	and	 indeed	more	 sterically	hindered	 system,	a	
radical	 acceptor	 derived	 from	 estrone	 was	 subjected	 to	 the	
reaction	 conditions,	which	 afforded	 hexacyclic	 compound	48,	
isolated	as	a	single	diastereomer	in	22%	yield.	The	relative	
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Scheme	4	Spirocyclic	3,4-dihydroquinolin-2-ones.	
stereochemistry	of	modified	steroid	48	was	confirmed	by	 the	
observation	 of	 NOE	 correlations	 between	 the	 α-keto	 methyl	
group	 and	 one	 of	 the	 α-amido	 protons,	 and	 one	 of	 the	
cyclopentanone	methylene	protons	with	the	aryl	proton	ortho-	
to	the	chlorine	atom.	
	 The	proposed	mechanistic	cycle	for	this	reaction	process	is	
depicted	 in	 Scheme	 5.	 Visible	 light	 irradiation	 of	 the	 Ir
III
	
photocatalyst	 Ir(ppy)3	 would	 lead	 to	 the	 long-lived	
photoexcited	 state	 Ir
III
*	 (49)	 [τ	 =	 1.9	 μs]	 which	 is	 a	 strong	
single-electron	reductant	[E1/2	(Ir
IV+
/Ir
III*
)	=	–1.73	V	vs	Saturated	
Calomel	 Electrode	 (SCE)]	 well-capable	 of	 reducing	 the	 N-
hydroxyphthalimido	oxamide	to	the	transient	radical	anion	50,	
which	 can	 then	 undergo	 homolytic	 cleavage	 with	 the	
concomitant	 loss	 of	 CO2	 and	 phthalimide	 anion	 to	 afford	
carbamoyl	 radical	 intermediate	 1.
35
	 The	 nucleophilic	
carbamoyl	 radical	 1	 is	 then	 trapped	 by	 an	 electron-deficient	
alkene	 51	 generating	 the	 electrophilic	 conjugate	 radical	 52	
which	can	cyclize	onto	the	anilide	to	produce	cyclohexadienyl	
radical	53.	Oxidation	of	the	electron-rich	radical	intermediate	
Scheme	5	Proposed	mechanism.		
	53	by	the	oxidized-state	photocatalyst	Ir
IV+
	(57)	[E1/2(Ir
IV+
/Ir
III
)	=	
+0.77	 V	 vs	 (SCE)]	 would	 regenerate	 the	 ground-state	 Ir
III	
photocatalyst	and	liberate	cyclohexadienyl	cation	55	which	can	
rearomatize	with	 loss	of	 a	proton	 (most	 likely	 to	phthalimide	
anion)	to	afford	the	3,4-dihydroquinolin-2-one	product.
35
	
Finally,	after	consideration	of	the	reaction	mechanism,	we	
proposed	an	extension	of	the	methodology	to	target	aromatic	
qunolin-2-ones,	important	targets	which	can	be	considered	as	
a	privileged	structure	for	lead	synthesis	in	the	pharmaceutical	
industry.
21–23,25
	 We	 hypothesized	 that	 by	 employing	 an	 α-
chloro	radical	acceptor	 in	 the	reaction	process,	elimination	of	
HCl	might	 be	 possible	 from	 the	 initially	 formed	 4-chloro-3,4-
dihydroquinolin-2-ones	 to	 provide	 access	 to	 quinolin-2-one	
products	(Scheme	6).	
In	 the	 event,	 quinolin-2-ones	 56–58	 were	 isolated	 in	 25–
59%	 yield	 (Scheme	 7).	Whilst	modest,	 these	 results	 highlight	
the	 structural	 diversity	 accessible	 under	 our	 standard	 set	 of	
reaction	conditions.	
Conclusions	
We	have	developed	a	novel	 reductive	 approach	 to	 access	
carbamoyl	 radicals	 from	 N-hydroxyphthalimido	 oxamides	
under	photoredox	catalysis.	This	strategy	allows	access	to	3,4-
dihydroquinolin-2-ones	 via	 an	 intermolecular	
addition/cyclization	of	carbamoyl	radicals	with	electron		
Scheme	6	Proposed	quinolin-2-one	synthesis.	
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Scheme	7	Quinoline-2-ones.	
deficient	olefins	in	a	mild,	redox-neutral	manner.	Functionality	
can	be	introduced	at	all	positions	of	the	3,4-dihydroquinolin-2-
one	 core	 and	 spirocyclic	 3,4-dihydroquinolin-2-ones	 can	 be	
readily	 accessed.	 In	 addition,	 by	 using	 α-chloro	 radical	
acceptors,	 aromatic	 quinolin-2-ones	 can	 also	 be	 produced.	 It	
should	 be	 emphasized	 that	 all	 of	 the	 reported	 results	 were	
conducted	 under	 a	 standard	 set	 of	 reaction	 conditions	 and	
that	optimization	of	the	process	should	be	possible	on	a	case-
by-case	basis.	We	are	currently	exploring	this	methodology	for	
applications	 in	 target	 synthesis,	 the	 results	 of	 which	 will	 be	
reported	 in	 due	 course.	 Finally,	 it	 is	 our	 hope	 that	 this	
reductive	 approach	 to	 access	 carbamoyl	 radicals	 will	 enable	
the	development	of	new	chemistry,	particularly	redox-neutral	
processes	in	the	future.	
Experimental	
Except	 where	 stated,	 all	 reagents	 were	 purchased	 from	
commercial	 sources	 and	 used	 without	 further	 purification.	
Liquid	 electron-deficient	 olefins	 containing	 radical	 inhibitors	
were	 distilled	 prior	 to	 use	 and	 stored	 at	 –20	 ˚C.	 THF	 and	
toluene	were	dried	on	an	Innovative	Technology	Inc.	PureSolv	
Solvent	 Purification	 System.	
1
H	 NMR	 and	
13
C	 NMR	 spectra	
were	 recorded	 on	 a	 JEOL	 ECX400	 or	 JEOL	 ECS400	
spectrometer,	 operating	 at	 400	 MHz	 and	 100	 MHz,	
respectively.	 All	 spectral	 data	 were	 acquired	 at	 295	 K.	
Chemical	 shifts	 are	 reported	 in	 parts	 per	 million	 (ppm,	 δ),	
downfield	from	tetramethylsilane	(TMS,	δ	=	0.00	ppm)	and	are	
referenced	 to	 residual	 solvent	 (CDCl3,	 δ	 =	 7.26	 ppm	 (
1
H)	 and	
77.16	ppm	(
13
C)).	Coupling	constants	 (J)	are	reported	 in	Hertz	
(Hz).	 The	 multiplicity	 abbreviations	 used	 are:	 br	 broad,	 s	
singlet,	 d	 doublet,	 t	 triplet,	 q	 quartet,	 m	 multiplet,	 comp	
overlapping	 multiplet	 of	 magnetically	 non-equivalent	 nuclei,	
app	 apparent.	 Signal	 assignment	was	 achieved	 by	 analysis	 of	
DEPT,	 COSY,	 HMBC	 and	 HSQC	 experiments	 where	 required.	
Infrared	 (IR)	 spectra	were	 recorded	on	a	PerkinElmer	UATR	2	
spectrometer,	 either	 as	 a	 compressed	 solid	 or	 a	 thin	 film	
dispersed	 from	CH2Cl2	 or	 CDCl3.	 High-resolution	mass-spectra	
were	 obtained	 by	 the	 University	 of	 York	 Mass	 Spectrometry	
Service,	 using	 electrospray	 ionization	 (ESI)	 on	 a	 Bruker	
Daltonics,	 Micro-tof	 spectrometer.	 Melting	 points	 were	
determined	 using	 Gallenkamp	 apparatus.	 Thin	 layer	
chromatography	was	carried	out	on	Merck	silica	gel	60F254	pre-
coated	aluminum	foil	sheets	and	were	visualized	using	UV	light	
(254	 nm)	 and	 stained	 with	 basic	 aqueous	 potassium	
permanganate.	Column	chromatography	was	carried	out	using	
Fluka	 silica	 gel	 (SiO2),	 35–70	 µm,	 60	 Å,	 under	 a	 light	 positive	
pressure,	eluting	with	the	specified	solvent	system.	
General	experimental		
General	procedure	A:	for	the	synthesis	of	oxamides		
Based	 upon	 the	 reported	 procedure,
14,36
	 oxalyl	 chloride	 (3.81	 g,	
2.54	 mL,	 30.0	 mmol)	 was	 added	 drop-wise	 to	 a	 solution	 of	 N-
hydroxyphthalimide	(979	mg,	6.0	mmol)	in	THF	(100	mL)	at	–78	˚C.	
After	 the	addition	was	complete,	 the	 reaction	was	stirred	at	 rt	 for	
18	 h	 then	 concentrated	 under	 reduced	 pressure	 and	 dried	 under	
high	 vacuum	 (in	 the	 dark)	 for	 1	 h.	 The	 off-white	 residue	 was	 re-
dissolved	 in	 THF	 (100	mL),	 cooled	 to	 –78	 ˚C	 and	 a	 solution	of	 the	
requisite	 aniline	 (6.0	 mmol)	 and	 pyridine	 (475	 mg,	 485	 mL,	 6.0	
mmol)	 in	 THF	 (5	mL)	was	 added	 drop-wise	 and	 the	 reaction	 then	
allowed	to	warm	to	0	˚C.	The	reaction	was	stirred	at	0	˚C	for	2	h	and	
then	 at	 rt	 for	 the	 period	 noted	 before	 being	 concentrated	 under	
reduced	pressure	and	the	residue	partitioned	between	EtOAc	(400	
mL)	and	HCl	(10%	aq,	100	mL).	The	organic	 layer	was	washed	with	
sat.	 aq.	 NaHCO3	 (4	 x	 100	 mL),	 dried	 (MgSO4)	 and	 concentrated	
under	reduced	pressure	and	the	residue	purified	by	recrystallization	
from	 the	 solvent	 indicated	 to	 afford	 the	 corresponding	 oxamides	
which	were	found	to	be	bench	stable,	but	were	stored	 in	the	dark	
as	a	precaution.	
General	procedure	B:	for	the	synthesis	of	3,4-dihydroquinolin-2-
ones	14–48	and	quinolin-2-ones	56–58.	
An	 8	 mL	 vial	 equipped	 with	 a	 PTFE	 septum	 and	 a	 magnetic	
stirrer	 bar	 was	 charged	 with	 the	 requisite	 oxamide	 (0.24	
mmol),	 electron-deficient	olefin	 (if	 solid,	0.36	mmol)	 and	 fac-
tris[2-phenylpyridinato-C2,N]iridium(III)	 [Ir(ppy)3]	 (3.1	 mg,	
0.0048	mmol).	 The	 vial	 was	 purged	with	 Ar,	 then	 toluene	 (6	
mL)	 was	 added	 and	 the	mixture	 was	 sparged	with	 Ar	 for	 10	
min	with	 stirring.	 After	 sparging	was	 complete,	 the	 electron-
deficient	 olefin	 (if	 liquid,	 0.36	 mmol)	 was	 added	 and	 the	
septum	additionally	sealed	with	paraffin	film.	The	reaction	was	
irradiated	 with	 a	 60	 W	 blue	 LED	 floodlight	 for	 24	 h,	 with	
stirring	 and	 cooling	 from	 a	 small	 fan	 to	maintain	 an	 ambient	
temperature.	The	mixture	was	partitioned	between	EtOAc	(3	x	
50	mL)	and	 sat.	 aq.	NH4Cl	 (50	mL)	and	 the	 combined	organic	
layers	 were	 dried	 (MgSO4)	 and	 concentrated	 under	 reduced	
pressure.	 The	 residue	 was	 purified	 by	 silica	 gel	 flash	 column	
chromatography,	eluting	with	the	solvents	 indicated	to	afford	
3,4-dihydroquinolin-2-ones	14–48	and	quinolin-2-ones	56–58.	
Compound	synthesis	
1,3-Dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-
oxoacetate	 (11).	 Prepared	 according	 to	 general	 procedure	 A	
using	N-methylaniline	(643	mg,	650	mL,	6.0	mmol)	and	stirring	
at	rt	for	2	h	to	afford	oxamide	11	(1.47	g,	76%)	as	pale	yellow	
needles	 after	 recrystallization	 from	 toluene:	 mp	 156–158	 ˚C;	
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1
H	 NMR	 (400	MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers)	 7.98–7.92	 (m,	
0.16H),	7.88–7.80	(comp,	2H),	7.78–7.72	(m,	1.84H),	7.52–7.46	
(m,	2H),	7.46–7.40	(m,	1H),	7.40–7.34	(m,	2H),	3.61	(s,	0.24H),	
3.46	(s,	2.76H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	(ppm)	(rotamers)	
160.9,	158.2,	157.6,	140.3,	135.3	 (minor),	135.0,	130.2,	129.6	
(minor),	 129.1,	 128.8,	 128.0	 (minor),	 126.6,	 125.4	 (minor),	
124.4	 (minor),	 124.2,	 38.8,	 36.9;	 IR	 (film,	 νmax/cm
-1
)	 1820,	
1791,	1743,	1671,	1492,	1351,	1127,	1088,	1009;	HRMS	(ESI
+
)	
m/z	 calcd.	 for	 C17H12N2NaO5	 [M+Na]
+
	 347.0638,	 found	
347.0625.	
1,3-Dioxoisoindolin-2-yl	 2-(methyl(4-(trifluoromethyl)	
phenyl)amino)-2-oxoacetate.	 Prepared	 according	 to	 general	
procedure	A	using	4-(trifluoromethyl)-N-methylaniline	(1.05	g,	
848	 mL,	 6.0	 mmol)	 and	 stirring	 at	 rt	 for	 16	 h	 to	 afford	 the	
oxamide	 (1.27	 g,	 54%)	 as	 colorless	 microcrystals	 after	
recrystallization	 from	 toluene:	mp	 148–150	 ˚C;	
1
H	NMR	 (400	
MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers)	 7.99–7.93	 (m,	 0.26H),	 7.89–
7.82	(comp,	2H),	7.81–7.71	(comp,	3.74H),	7.56	(d,	J	=	8.3	Hz,	
0.26H),	 7.51	 (d,	 J	 =	 8.3	 Hz,	 1.74H),	 3.65	 (s,	 0.39H),	 3.49	 (s,	
2.61H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers,	minor	
omitted	for	clarity)	160.9,	157.8,	157.2,	143.5	(m),	135.1,	130.9	
(q,	JC-F	=	33.1	Hz),	128.7,	127.4	(q,	 JC-F	=	3.7	Hz),	126.6,	124.3,	
123.7	(q,	JC-F	=	272.4	Hz),	36.8;	IR	(film,	νmax/cm
-1
)	1787,	1748,	
1676,	1611,	1325,	1156,	1098,	1005;	HRMS	(ESI
+
)	m/z	calcd.	for	
C18H11F3N2NaO5	[M+Na]
+	
	415.0512,	found	415.0496.	
1,3-Dioxoisoindolin-2-yl	 2-((4-
fluorophenyl)(methyl)amino)-2-oxoacetate.	 Prepared	
according	 to	 general	 procedure	 A	 using	 4-fluoro-N-
methylaniline	(751	mg,	722	mL,	6.0	mmol)	and	stirring	at	rt	for	
14	h	to	afford	the	oxamide	(636	mg,	31%)	as	off-white	plates	
after	 recrystallization	 from	 toluene:	mp	138–140	 ˚C;	
1
H	NMR	
(400	 MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers)	 7.98–7.93	 (m,	 0.16H),	
7.88–7.81	 (comp,	 2H),	 7.80–7.73	 (m,	 1.84H),	 7.39–7.33	 (m,	
2H),	7.17	(app	t,	J	=	8.5	Hz,	2H),	3.59	(s,	0.24H),	3.43	(s,	2.76H);	
13
C	NMR	 (100	MHz,	CDCl3)	δ	 (ppm)	162.7	 (d,	 JC-F	 =	249.5	Hz),	
160.9,	 158.1,	 157.6,	 136.3	 (d,	 JC-F	 =	 3.2	 Hz),	 135.3	 (minor),	
135.0,	134.6	 (minor),	129.2	 (minor),	128.8,	128.7	 (d,	JC-F	=	9.0	
Hz),	 128.4	 (minor),	 124.5	 (minor),	 124.2,	 117.3	 (d,	 JC-F	 =	 23.0	
Hz),	 37.1;	 IR	 (film,	 νmax/cm
-1
)	 1817,	 1790,	 1743,	 1671,	 1507,	
1350,	 1226,	 1158,	 1128,	 1088;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C17H11FN2NaO5	[M+Na]
+	
	365.0544,	found	365.0534.	
1,3-Dioxoisoindolin-2-yl	 2-((4-chlorophenyl)(methyl)	
amino)-2-oxoacetate.	 Prepared	 according	 to	 general	
procedure	A	using	4-chloro-N-methylaniline	(850	mg,	726	mL,	
6.0	mmol)	and	stirring	at	rt	for	4	h	to	afford	the	oxamide	(1.25	
g,	 58%)	 as	 colorless	 cubes	 after	 recrystallization	 from	 EtOAc:	
mp	166–168	˚C;	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	(rotamers)	
7.86–7.82	(m,	2H),	7.79–7.74	(m,	2H),	7.46–7.41	(m,	2H),	7.35–
7.29	 (m,	 2H),	 3.59	 (s,	 0.30H)	 3.43	 (s,	 2.70H);	
13
C	 NMR	 (100	
MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers)	 160.9,	 157.9,	 157.3,	 138.9,	
135.3	(minor),	135.0,	134.9,	130.4,	129.7	(minor),	128.7,	127.8,	
126.6	 (minor),	 124.4	 (minor),	 124.2,	 38.6	 (minor),	 36.9;	 IR	
(film,	 νmax/cm
-1
)	 1816,	 1789,	 1743,	 1491,	 1467,	 1350,	 1091,	
1015;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	 C17H11
35
ClN2NaO5	 [M+Na]
+	
381.0249,	found	381.0247.	
1,3-Dioxoisoindolin-2-yl	 2-(methyl(p-tolyl)amino)-2-
oxoacetate.	Prepared	according	to	general	procedure	A	using	
N-methyl-p-toluidine	(727	mg,	759	mL,	6.0	mmol)	and	stirring	
at	rt	for	2.5	h	to	afford	the	oxamide	(1.46	g,	72%)	as	colorless	
needles	 after	 recrystallization	 from	 toluene:	 mp	 152–154	 ˚C;	
1
H	 NMR	 (400	MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers)	 7.97–7.92	 (m,	
0.15H),	7.87–7.80	(comp,	2H),	7.78–7.72	(m,	1.85H),	7.29–7.23	
(comp,	 4H),	 3.58	 (s,	 0.23H),	 3.43	 (s,	 2.77H),	 2.39	 (s,	 2.77H),	
2.38	(s,	0.23H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	(ppm)	(rotamers)	
161.0,	158.2,	157.6,	139.2,	137.8,	135.3	 (minor),	134.9,	134.6	
(minor),	 130.8,	 130.2	 (minor),	 128.9,	 126.2,	 125.2	 (minor),	
124.4	(minor),	124.2,	123.7	(minor),	38.9	(minor),	37.0,	21.3;	IR	
(film,	 νmax/cm
-1
)	 3132,	 1785,	 1739,	 1675,	 1463,	 1181,	 1131,	
1190,	1006;	HRMS	(ESI
+
)	m/z	calcd.	for	C18H14N2NaO5	[M+Na]
+	
	
361.0795,	found	361.0789.	
1,3-Dioxoisoindolin-2-yl	 2-((4-methoxyphenyl)(methyl)	
amino)-2-oxoacetate.	 Prepared	 according	 to	 general	
procedure	 A	 using	 4-methyoxy-N-methylaniline	 (823	 mg,	 6.0	
mmol)	 and	 stirring	 at	 rt	 for	 18	 h	 to	 afford	 the	 oxamide	 (829	
mg,	 39%)	 as	 fine	 white	 needles	 after	 recrystallisation	 from	
EtOAc:	mp	135–137	 ˚C;	 1H	NMR	 (400	MHz,	 CDCl3)	δ	 (ppm)	
(rotamers)	7.95–7.92	(m,	0.15H),	7.84–7.79	(comp,	1.95H),	
7.78–7.73	(m,	1.90H),	7.31–7.26	(m,	2H),	6.99–6.94	(m,	2H),	
3.85	 (s,	 2.70H),	 3.82	 (s,	 0.30H),	 3.57	 (s,	 0.30H),	 3.40	 (s,	
2.70H);	 13C	 NMR	 (100	 MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers)	
160.9,	 160.0,	 159.3,	 157.7,	 135.3	 (minor),	 134.9,	 133.0,	
128.8,	 128.0,	 126.7	 (minor),	 124.4	 (minor),	 124.1,	 115.3,	
114.8	 (minor),	 55.7,	 37.1;	 IR	 (film,	 νmax/cm-1)	 1816,	 1788,	
1743,	1672,	1511,	1249,	1103;	HRMS	(ESI+)	m/z	 calcd.	 for	
C18H14N2NaO6	[M+Na]+	377.0744,	found	377.0736.	
1,3-Dioxoisoindolin-2-yl	 2-(methyl(m-tolyl)amino)-2-
oxoacetate.	Prepared	according	to	general	procedure	A	using	
N-methyl-m-toluidine	(727	mg,	760	mL,	6.0	mmol)	and	stirring	
at	 rt	 for	 30	min	 to	 afford	 the	 oxamide	 (1.59	 g,	 79%)	 as	 off-
white	 microcrystals	 after	 recrystallization	 from	 toluene:	 mp	
120-123	 ˚C;	
1
H	NMR	 (400	MHz,	CDCl3)	δ	 (ppm)	7.98–7.92	 (m,	
0.17H),	7.88–7.80	(comp,	2H),	7.78–7.72	(m,	1.83H),	7.36	(app	
t,	J	=	8.2	Hz,	1H),	7.25–7.14	(comp,	3H),	3.59	(s,	0.25H),	3.44	(s,	
2.75H),	 2.43	 (s,	 2.75H),	 2.40	 (s,	 0.25H);	
13
C	 NMR	 (100	 MHz,	
CDCl3)	δ	(ppm)	160.9,	158.2,	157.6,	140.6,	140.3,	134.9,	130.0,	
129.8,	128.9,	127.0,	124.2,	123.3,	36.9,	21.4;	IR	(film,	νmax/cm
-
1
)	 1807,	 1782,	 1737,	 1669,	 1589,	 1184,	 1156,	 1130,	 1097,	
1027;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	 C18H14N2NaO5	 [M+Na]
+	
	
361.0795,	found	361.0793.	
1,3-Dioxoisoindolin-2-yl	 2-(methyl(o-tolyl)amino)-2-
oxoacetate.	Prepared	according	to	general	procedure	A	using	
N-methyl-o-toluidine	(727	mg,	741	mL,	6.0	mmol)	and	stirring	
at	rt	for	16	h	to	afford	the	oxamide	(1.10	g,	54%)	as	pale	yellow	
microcrystals	after	recrystallization	from	toluene:	mp	123–125	
˚C;	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	(rotamers)	7.97–7.93	(m,	
0.15H),	7.88–7.77	(comp,	2H),	7.77–7.71	(m,	1.85H),	7.41–7.25	
(comp,	 4H),	 3.53	 (s,	 0.23H),	 3.35	 (s,	 2.77H),	 2.36	 (s,	 2.77H),	
2.29	(s,	0.23H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	(ppm)	(rotamers)	
160.9,	 157.9	 (2C),	 138.8,	 136.5,	 135.3	 (minor),	 134.9,	 131.8,	
130.4	 (minor),	 130.0,	 129.2	 (minor),	 128.8,	 (2C),	 127.7,	 124.5	
(minor),	 124.2,	 36.1,	 17.5;	 IR	 (film,	 νmax/cm
-1
)	 1819,	 1790,	
1744,	1678,	1492,	1349,	1185,	1157,	1131,	1077,	1004;	HRMS	
(ESI
+
)	m/z	 calcd.	 for	 C18H14N2NaO5	 [M+Na]
+
	 361.0795,	 found	
361.0794.	
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1,3-Dioxoisoindolin-2-yl	 2-((2-fluorophenyl)(methyl)	
amino)-2-oxoacetate.	 Prepared	 according	 to	 general	
procedure	A	using	N-(2-fluorophenyl)-N-methylamine	(751	mg,	
6.0	 mmol)	 and	 stirring	 at	 rt	 for	 18	 h	 to	 afford	 the	 oxamide	
(1.38	 g,	 67%)	 as	 colorless	microcrystals	 after	 recrystallization	
from	 toluene:	 mp	 134–136	 ˚C;	
1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	
(ppm)	(rotamers)	7.98–7.92	(m,	0.20H),	7.88–7.79	(comp,	2H),	
7.78–7.72	(m,	1.80H),	7.49–7.33	(comp,	2H),	7.30–7.19	(comp,	
2H),	3.59	(s,	0.30H),	3.42	(s,	2.70H);	
13
C	NMR	(100	MHz,	CDCl3)	
δ	(ppm)	(rotamers)	161.3	(minor),	160.8,	158.2	(d,	JC-F	=	252.0	
Hz),	 157.6	 (2C),	 135.3	 (minor),	 135.0,	 131.4	 (d,	 JC-F	 =	 7.9	Hz),	
130.4	 (d,	 JC-F	 =	 8.0	 Hz)	 (minor),	 129.6,	 129.1	 (minor),	 128.8	
(minor),	128.7,	128.4	(d,	JC-F	=	20.2	Hz)	(minor),	127.9	(d,	JC-F	=	
12.9	Hz),	125.5	(d,	JC-F	=	4.1	Hz),	125.1	(d,	JC-F	=	3.6	Hz)	(minor),	
124.4	(minor),	124.2,	117.2	(d,	JC-F	=	19.5	Hz),	117.2	(JC-F	=	19.6	
Hz)	(minor),	38.6	(d,	JC-F	=	2.0	Hz)	(minor),	36.4	(d,	JC-F	=	2.0	Hz);	
IR	(film,	νmax/cm
-1
)	1819,	2789,	1743,	1686,	1499,	1185,	1163,	
1134,	 1111,	 1078,	 1006;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C17H11FN2NaO5	[M+Na]
+	
	365.0544,	found	365.0528.	
1,3-Dioxoisoindolin-2-yl	 2-(benzyl(phenyl)amino)-2-
oxoacetate.	Prepared	according	to	general	procedure	A	using	
N-benzylaniline	 (1.00	 g,	 1.04	mL,	 6.0	mmol)	 and	 stirring	 at	 rt	
for	4	h	to	afford	the	oxamide	(1.65	g,	69%)	as	colorless	cubes	
after	 recrystallization	 from	 EtOAc:	mp	 131–133	 ˚C;	
1
H	 NMR	
(400	MHz,	CDCl3)	δ	(ppm)	(rotamers)	7.83–7.78	(m,	2H),	7.77–
7.71	 (m,	 2H),	 7.42–7.37	 (comp,	 3H),	 7.33–7.28	 (comp,	 3H),	
7.28–7.23	(m,	2H),	7.21–7.16	(m,	2H),	5.11	(s,	0.10H),	5.03	(s,	
1.90H);	
13
C	NMR	 (100	MHz,	CDCl3)	 δ	 (ppm)	 (rotamers)	 160.9,	
158.1,	157.7,	138.6,	135.3,	135.2	 (minor),	134.9,	130.0,	129.5	
(minor),	 129.3,	 129.0,	 128.8,	 128.8,	 128.5	 (minor),	 128.2,	
127.9,	 127.1	 (minor),	 124.4	 (minor),	 124.1,	 53.1;	 IR	 (film,	
νmax/cm
-1
)	 1815,	 1788,	 1743,	 1672,	 1595,	 1494,	 1113,	 1077;	
HRMS	 (ESI
+
)	m/z	 calcd.	 for	 C23H16N2NaO5	 [M+Na]
+	
423.0951,	
found	423.0967.	
1,3-Dioxoisoindolin-2-yl-2-(allyl(phenyl)amino)-2-
oxoacetate.	Prepared	according	to	general	procedure	A	using	
N-allylaniline	(799	mg,	814	mL,	6.0	mmol)	and	stirring	at	rt	for	
4	h	to	afford	the	oxamide	(1.20	g,	57%)	as	colorless	cubes	after	
recrystallization	 from	 EtOAc:	 mp	 138–140	 ˚C;	
1
H	 NMR	 (400	
MHz,	 CDCl3)	 δ	 (ppm)	 (rotamers)	 7.96–7.92	 (m,	 0.10H),	 7.86–
7.79	(comp,	2H),	7.77–7.72	(m,	1.90H),	7.50–7.41	(comp,	3H),	
7.36–7.34	 (m,	2H),	5.90	 (ddt,	 J	 =	17.2,	9.8,	6.3	Hz,	1H),	5.27–
5.10	(comp,	2H),	4.55–4.51	(m,	0.10H),	4.46	(dt,	J	=	6.3,	1.2	Hz,	
1.90H);	
13
C	NMR	 (100	MHz,	CDCl3)	 δ	 (ppm)	 (rotamers)	 160.9,	
158.0,	157.4,	138.9,	135.3	 (minor),	135.0,	131.1,	130.1,	129.6	
(minor),	 129.2,	 128.8,	 127.6,	 126.8	 (minor),	 124.4	 (minor),	
124.2,	119.8,	52.2;	IR	(film,	νmax/cm
-1
)	1815,	1788,	1743,	1672,	
1596,	 1494,	 1185,	 1106;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C19H14N2NaO5	[M+Na]
+	
	373.0795,	found	373.0778.	
1,3-Dioxoisoindolin-2-yl	 2-((tert-butoxycarbonyl)(phenyl)	
amino)-2-oxoacetate.	Based	upon	the	reported	procedure,
14,32	
oxalyl	chloride	(3.81	g,	2.54	mL,	30.0	mmol)	was	added	drop-
wise	 to	 a	 solution	 of	 N-hydroxyphthalimide	 (979	 mg,	 6.0	
mmol)	 in	 THF	 (100	 mL)	 at	 –78	 ˚C.	 After	 the	 addition	 was	
complete,	 the	 reaction	 was	 stirred	 at	 rt	 for	 18	 h	 then	
concentrated	 under	 reduced	 pressure	 and	 dried	 under	 high	
vacuum	(in	the	dark)	for	1	h	to	provide	an	off-white	residue.	
A	 solution	 of	 tert-butyl	 phenylcarbamate
37
	 (1.16	 g,	 6.0	
mmol)	 in	THF	(5	mL)	was	added	drop-wise	to	a	suspension	of	
sodium	 hydride	 (60%	 dispersion	 in	 mineral	 oil,	 0.480	 g,	 7.2	
mmol)	 in	THF	(40	mL)	at	0	°C	and	the	reaction	was	stirred	for	
30	min	 at	 this	 temperature.	 The	 resultant	 solution	 was	 then	
transferred	via	cannula	drop-wise	 into	a	solution	of	chloro	N-
phthalimidoyl	 oxalate	 in	 THF	 (100	 mL),	 at	 –78	 ˚C	 and	 the	
reaction	 then	 allowed	 to	 warm	 to	 0	 ˚C.	 The	 reaction	 was	
stirred	 at	 0	 ˚C	 for	 2	 h	 and	 then	 at	 rt	 for	 2	 h	 before	 being	
concentrated	 under	 reduced	 pressure	 and	 the	 residue	
partitioned	 between	 EtOAc	 (400	 mL)	 and	 critic	 acid	 solution	
(10%	aq,	100	mL).	The	organic	 layer	was	washed	with	sat.	aq.	
NaHCO3	 (4	x	100	mL),	dried	 (MgSO4)	and	concentrated	under	
reduced	pressure	and	the	residue	purified	by	 recrystallization	
from	 EtOAc	 to	 afford	 the	 oxamide	 (0.730	 g,	 30%)	 as	 white	
needles	 which	 were	 stored	 in	 the	 dark	 as	 a	 precaution:	 mp	
124–125	 ˚C	 (sublimes);	
1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	 (ppm)	
7.95-7.89	(m,	2H),	7.84-7.79	(m,	2H),	7.50-7.40	(m/comp,	3H),	
7.25-7.20	 (m,	 2H),	 1.48	 (s,	 9H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	
(ppm)	 161.1,	 159.3,	 157.3,	 151.7,	 135.1,	 134.6,	 129.4,	 129.3,	
128.9,	128.0,	124.3,	86.9,	27.8;	IR	(film,	νmax/cm
-1
)	1825,	1792,	
1741,	 1713,	 1294,	 1147,	 1052;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C21H18N2NaO7	[M+Na]
+
	433.1006,	found	433.1007.	
1,3-Dioxoisoindolin-2-yl-2-((3-methoxyphenyl)(methyl)	
amino)-2-oxoacetate.	 Prepared	 according	 to	 general	
procedure	 A	 using	 3-methyoxy-N-methylaniline	 (823	 mg,	 6.0	
mmol)	 and	 stirring	 at	 rt	 for	 18	 h	 to	 afford	 the	 oxamide	 (590	
mg,	28%)	as	a	white	powder	after	recrystallization	from	Et2O:	
mp	101–103	˚C;	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	(rotamers)	
7.96–7.92	(m,	0.15H),	7.87–7.79	(comp,	1.95H),	7.78–7.72	(m,	
1.90H),	 7.31–7.26	 (m,	 2H),	 7.38	 (t,	 J	 =	 8.1	Hz,	 1H),	 6.99–6.93	
(comp,	 2H),	 6.84	 (t,	 J	 =	 2.2	 Hz,	 1H),	 3.85	 (s,	 2.70H),	 3.82	 (s,	
0.30H),	 3.59	 (s,	 0.30H),	 3.44	 (s,	 2.70H);	
13
C	 NMR	 (100	 MHz,	
CDCl3)	 δ	 (ppm)	 (rotamers)	 160.9,	 160.8,	 158.1,	 157.5,	 141.4,	
135.3	 (minor),	 134.9,	 130.9,	 130.3	 (minor),	 128.8,	 124.4	
(minor),	 124.2,	 118.7,	 117.4	 (minor),	 115.3,	 111.8,	 111.3	
(minor),	 55.6,	 38.8	 (minor),	 36.9;	 IR	 (film,	 νmax/cm
-1
)	 1816,	
1788,	 1742,	 1672,	 1602;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C18H14N2NaO6	[M+Na]
+
	377.0744,	found	377.0734.	
Ethyl	 1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-4-
carboxylate	 (14).	 Prepared	 according	 to	 general	 procedure	 B	
using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-
oxoacetate	 (11)	 (77.8	mg,	0.24	mmol)	 and	ethyl	 acrylate	 (12)	
(36.0	 mg,	 39.3	 mL,	 0.36	 mmol)	 and	 eluting	 with	 3:2	
hexanes/EtOAc	 to	 give	 3,4-dihydroquinolin-2-one	 14	 (24	 mg,	
43%)	 as	 a	 pale	 yellow	 solid:	 Rf	 0.15	 (3:2	 hexanes/EtOAc);	mp	
67-69	˚C;	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	7.32	(app	t,	J	=	7.9	
Hz,	1H),	7.28–7.25	(m,	1H),	7.06	(app	t,	J	=	7.9	Hz,	1H),	7.01	(d,	
J	=	7.9	Hz,	1H),	4.24–4.06	(m,	2H),	3.85	(dd,	J	=	6.1,	4.7	Hz,	1H),	
3.36	(s,	3H),	3.03	(dd,	J	=	16.2,	4.7	Hz,	1H),	2.79	(dd,	J	=	16.2,	
6.1	Hz,	1H),	1.22	(t,	J	=	7.0	Hz,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	
(ppm)	 171.7,	 168.3,	 140.4,	 128.9,	 128.6,	 123.1,	 122.9,	 115.3,	
61.6,	 42.3,	 33.9,	 29.7,	 14.2;	 IR	 (film,	 νmax/cm
-1
)	 2919,	 1719,	
1667,	1597,	1464,	1414,	1367,	1193,	1142,	1018;	HRMS	(ESI
+
)	
m/z	 calcd.	 for	 C13H15NNaO3	 [M+Na]
+	
	 256.0944,	 found	
256.0940.	
Journal	Name	 	ARTICLE	
This	journal	is	©	The	Royal	Society	of	Chemistry	20xx	 J.	Name.,	2013,	00,	1-3	|	9 	
Please	do	not	adjust	margins	
Please	do	not	adjust	margins	
Methyl	 1,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinoline-4-
carboxylate	 (15).	 Prepared	 according	 to	 general	 procedure	 B	
using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-
oxoacetate	 (11)	 (77.8	 mg,	 0.24	 mmol)	 and	 methyl	
methacrylate	 (13)	 (36.0	mg,	38.5	mL,	0.36	mmol)	 and	eluting	
with	 1:1	 hexanes/Et2O	 to	 give	 3,4-dihydro-1H-quinolin-2-one	
15	 (39	 mg,	 70%)	 as	 a	 pale	 yellow	 solid:	 Rf	 0.12	 (1:1	
hexanes/Et2O);	 mp	 83–84	 ˚C;	
1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	
(ppm)	7.35–7.28	(comp,	2H),	7.09	(app	td,	J	=	7.7,	1.2	Hz,	1H),	
7.01	 (d,	 J	 =	7.7	Hz,	1H),	3.69	 (s,	3H),	3.37	 (s,	3H),	3.14	 (d,	 J	 =	
16.0	Hz,	 1H),	 2.57	 (d,	 J	 =	 16.0	Hz,	 1H),	 1.60	 (s,	 3H);	
13
C	NMR	
(100	MHz,	 CDCl3)	 δ	 (ppm)	 174.4,	 168.3,	 139.8,	 128.7,	 128.1,	
126.1,	 123.4,	 115.3,	 52.9,	 44.6,	 41.7,	 29.6,	 23.4;	 IR	 (film,	
νmax/cm
-1
)	 2921,	 1729,	 1674,	 1598,	 1469,	 1359,	 1268,	 1196,	
1160,	 1136,	 1102,	 1055;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C13H15NNaO3	[M+Na]
+	
	256.0944,	found	256.0940.	
Ethyl	 4-(diethoxyphosphoryl)-1-methyl-2-oxo-1,2,3,4-
tetrahydroquinoline-4-carboxylate	 (16).	 Prepared	 according	
to	 general	 procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-
(methyl(phenyl)amino)-2-oxoacetate	 (11)	 (77.8	 mg,	 0.24	
mmol)	 and	 ethyl	 2-(diethoxyphosphoryl)acrylate
38
	 (85.0	 mg,	
76.1	mL,	 0.36	mmol)	 and	 eluting	 with	 1:9	 hexanes/EtOAc	 to	
give	3,4-dihydro-1H-quinolin-2-one	16	 (65	mg,	73%)	as	a	pale	
yellow	 oil	 which	 solidified	 on	 standing:	 Rf	 0.18	 (1:9	
hexanes/EtOAc);	mp	 32-33	 ˚C;	
1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	
(ppm)	7.70	(d,	J	=	8.0	Hz,	1H),	7.34	(app	t,	J	=	8.0	Hz,	1H),	7.08	
(app	t,	J	=	8.0	Hz,	1H),	7.01	(d,	J	=	8.0	Hz,	1H)	4.28	(q,	J	=	7.0	Hz,	
2H),	4.19–3.99	(comp,	4H),	3.41	(dd,	J	=	24.9,	16.5	Hz,	1H),	3.34	
(s,	3H),	3.14	(dd,	J	=	16.5,	11.2	Hz,	1H),	1.27	(t,	J	=	7.0	Hz,	6H),	
1.20	 (t,	 J	 =	 7.0	 Hz,	 3H);	
13
C	 NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	
169.1	 (d,	 JC-P	=	1.5	Hz),	166.8	 (d,	 JC-P	=	6.6	Hz),	140.4	 (d,	 JC-P	=	
7.0	Hz),	129.4	(d,	JC-P	=	2.5	Hz),	129.0	(d,	JC-P	=	4.8	Hz),	123.1	(d,	
JC-P	 =	 2.4	Hz),	 120.0	 (d,	 JC-P	 =	 6.4	Hz),	 115.6	 (d,	 JC-P	 =	 1.4	Hz),	
63.6	(d,	JC-P	=	7.1	Hz),	63.5	(d,	JC-P	=	7.2	Hz),	62.8,	51.7	(d,	JC-P	=	
143.6	Hz),	36.1	(d,	JC-P	=	4.3	Hz),	29.7,	16.4	(2C,	d,	JC-P	=	6.2	Hz;	
d,	 JC-P	 =	 6.0	 Hz),	 14.1;	 IR	 (film,	 νmax/cm
-1
)	 2982,	 2934,	 1732,	
1675,	1597,	1462,	1364,	1247,	1215,	1039,	1015;	HRMS	(ESI
+
)	
m/z	calcd.	for	C17H25NO6P	[M+H]
+	
	370.1414,	found	370.1417.	
2,2,2-Trifluoroethyl	 1-methyl-2-oxo-1,2,3,4-tetrahydro	
quinoline-4-carboxylate	 (17).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-
(methyl(phenyl)amino)-2-oxoacetate	 (11)	 (77.8	 mg,	 0.24	
mmol)	and	2,2,2-trifluoroethyl	acrylate	(55.5	mg,	45.6	mL,	0.36	
mmol)	 and	 eluting	 with	 3:2	 hexanes/Et2OAc	 to	 give	 3,4-
dihydro-1H-quinolin-2-one	 17	 (33	 mg,	 48%)	 as	 an	 off-white	
solid:	Rf	0.23	(3:2	hexanes/EtOAc);	mp	93-95	˚C;	
1
H	NMR	(400	
MHz,	CDCl3)	δ	(ppm)	7.35	(app	t,	J	=	7.8	Hz,	1H),	7.28	(d,	J	=	7.8	
Hz,	 1H),	 7.08	 (app	 t,	 J	 =	 7.8	Hz,	 1H),	 7.03	 (d,	 J	 =	 7.8	Hz,	 1H),	
4.56–4.38	 (comp,	 2H),	 3.98	 (dd,	 J	 =	 6.3,	 3.9	 Hz,	 1H),	 3.36	 (s,	
3H),	3.06	 (dd,	 J	=	16.2,	3.9	Hz,	1H),	2.85	 (dd,	 J	=	16.2,	6.3	Hz,	
1H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	 170.2,	 167.6,	 140.4,	
129.5,	128.8,	124.2,	123.4,	121.4,	115.5,	61.0	 (q,	J	=	36.7	Hz),	
41.9,	 33.6,	 29.7;	 IR	 (film,	 νmax/cm
-1
)	 2923,	 1736,	 1660,	 1597,	
1465,	 1419,	 1382,	 1297,	 1164;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C13H12F3NNaO3	[M+Na]
+	
	310.0661,	found	310.0657.	
1-Methyl-4-(phenylsulfonyl)-3,4-dihydroquinolin-2(1H)-
one	(18).	Prepared	according	to	general	procedure	B	using	1,3-
dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-oxoacetate	
(11)	 (77.8	mg,	0.24	mmol)	and	phenyl	vinyl	 sulfone	 (60.6	mg,	
0.36	 mmol)	 and	 eluting	 with	 7:3→0:1	 hexanes/Et2O	 to	 give	
3,4-dihydro-1H-quinolin-2-one	 18	 (43	 mg,	 59%)	 as	 a	 pale	
yellow	 solid.	 Rf	 0.25	 (7:3	 hexanes/Et2O);	mp	 154–155	 ˚C;	
1
H	
NMR	 (400	MHz,	 CDCl3)	 δ	 (ppm)	 7.58	 (tt,	 J	 =	 7.5,	 1.3	Hz,	 1H),	
7.54–7.49	 (m,	2H),	 7.46–7.36	 (comp,	4H),	 7.13	 (app	 t,	 J	 =	 7.3	
Hz,	1H),	6.81	(d,	J	=	8.3	Hz,	1H),	4.33	(d,	J	=	7.7	Hz,	1H),	3.42	(d,	
J	=	17.7	Hz,	1H)	3.02	(dd,	J	=	17.7,	7.7	Hz,	1H),	2.80	(s,	3H);	
13
C	
NMR	 (100	 MHz,	 CDCl3)	 δ	 (ppm)	 165.1,	 141.0,	 136.0,	 134.3,	
131.8,	 130.9,	 129.6,	 128.9,	 123.3,	 116.2,	 115.2,	 63.2,	 32.0,	
29.2;	 IR	 (film,	νmax/cm
-1
)	2924,	1668,	1595,	1478,	1373,	1303,	
1291,	 1138,	 1080;	 HRMS	 (ESI
+
)	m/z	 calcd.	 for	 C16H15NNaO3S	
[M+Na]
+	
	324.0665,	found	324.0651.	
1-Methyl-4-propionyl-3,4-dihydroquinolin-2(1H)-one	 (19).	
Prepared	 according	 to	 general	 procedure	 B	 using	 1,3-
dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-oxoacetate	
(11)	 (77.8	 mg,	 0.24	 mmol)	 and	 ethyl	 vinyl	 ketone	 (30.3	 mg,	
35.6	mL,	0.36	mmol)	and	eluting	with	1:4	hexanes/Et2O	to	give	
3,4-dihydroquinolin-2-one	 19	 (34	 mg,	 65%)	 as	 a	 pale	 yellow	
solid.	 Rf	 0.20	 (1:4	hexanes/Et2O);	mp	93–95	 ˚C;	
1
H	NMR	 (400	
MHz,	CDCl3)	δ	(ppm)	7.33–7.25	(comp,	2H),	7.06	(t,	J	=	7.9	Hz,	
1H),	6.98	(d,	J	=	7.9	Hz,	1H),	3.82	(dd,	J	=	6.1,	2.8	Hz,	1H),	3.30	
(s,	3H),	3.02	(dd,	J	=	16.1,	2.8	Hz,	1H),	2.68	(dd,	J	=	16.1,	6.1	Hz,	
1H),	 2.59–2.41	 (comp,	 2H),	 0.96	 (t,	 J	 =	 7.2	 Hz,	 3H);	
13
C	NMR	
(100	 MHz,	 CDCl3)	 δ	 (ppm)	 208.2,	 168.8,	 140.5,	 128.9	 (2C),	
123.1	(2C),	115.3,	49.0,	33.4,	33.1,	29.5,	7.6;	IR	(film,	νmax/cm
-1
)	
2933,	1702,	1670,	1595,	1462,	1413,	1371,	1279,	1187,	1144,	
1115;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	 C13H15NNaO2	 [M+Na]
+	
	
240.0995,	found	240.0996.		
1-Methyl-2-oxo-1,2,3,4-tetrahydroquinoline-4-carbonitrile	
(20).	 Prepared	 according	 to	 general	 procedure	 B	 using	 1,3-
dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-oxoacetate	
(11)	(77.8	mg,	0.24	mmol)	and	acrylonitrile	(19.1	mg,	23.7	mL,	
0.36	 mmol)	 and	 eluting	 with	 3:7	 hexanes/Et2O	 to	 give	 3,4-
dihydroquinolin-2-one	20	 (36	mg,	81%)	as	a	pale	yellow	solid:	
Rf	 0.15	 (2:3	 hexanes/Et2O);	mp	88–90	 ˚C;	
1
H	NMR	 (400	MHz,	
CDCl3)	δ	(ppm)	7.48	(dt,	J	=	7.6,	1.0	Hz,	1H),	7.44–7.38	(m,	1H),	
7.16	(td,	7.6,	1.0	Hz,	1H),	7.06	(dd,	J	=	8.2,	0.6	Hz,	1H),	4.18	(dd,	
J	=	10.6,	5.4	Hz,	1H),	3.38	(s,	3H),	3.02	(dd,	J	=	16.0,	5.4	Hz,	1H),	
2.93	 (dd,	 J	 =	 16.0,	 10.6	Hz,	 1H);	
13
C	NMR	 (100	MHz,	CDCl3)	 δ	
(ppm)	 166.4,	 139.7,	 130.0,	 127.0,	 123.9,	 119.5,	 118.2,	 115.7,	
34.9,	 30.0,	 28.4;	 IR	 (film,	 νmax/cm
-1
)	 2924,	 2247,	 1742,	 1728,	
1670,	 1600,	 1472,	 1459,	 1359,	 1272,	 1135;	 HRMS	 (ESI
+
)	m/z	
calcd.	for	C11H10N2NaO	[M+Na]
+
	209.0685,	found	209.0686.	
5-Methyl-4-oxo-1,2,3,3a,4,5-hexahydro-9bH-cyclopenta[c]	
quinolone-9b-carbonitrile	(23).	Prepared	according	to	general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-
(methyl(phenyl)amino)-2-oxoacetate	11	 (77.8	mg,	0.24	mmol)	
and	1-cyclopentenecarbonitrile	(33.5	mg,	35.5	mL,	0.36	mmol)	
and	 eluting	 with	 1:1	 hexanes/Et2O	 to	 give	 3,4-dihydro-1H-
quinolin-2-one	23	 (20	mg,	 45%)	 as	 a	white	 solid:	 Rf	 0.39	 (2:3	
hexanes/Et2O);	mp	 112–114	 ˚C;	
1
H	 NMR	 (400	MHz,	 CDCl3)	 δ	
(ppm)	7.60	(dd,	J	=	7.6,	1.5	Hz,	1H),	7.43–7.36	(m,	1H),	7.17	(td,	
J	=	7.6,	1.1	Hz,	1H),	7.05	(dd,	J	=	8.2,	0.8	Hz,	1H),	3.40	(s,	3H),	
3.23	(dd,	J	=	8.2,	4.3	Hz,	1H),	2.54–2.32	(comp,	3H),	2.14–1.93	
(comp,	 2H),	 1.87–1.74	 (m,	 1H);	
13
C	 NMR	 (100	MHz,	 CDCl3)	 δ	
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(ppm)	 168.0,	 138.1,	 129.9,	 127.6,	 123.9,	 122.0,	 121.0	 115.5,	
49.2,	 45.4,	 39.3,	 30.2,	 28.4,	 21.6;	 IR	 (film,	 νmax/cm
-1
)	 2236,	
1743,	16667,	1600,	1457,	1356,	1273,	1124;	HRMS	 (ESI
+
)	m/z	
calcd.	for	C14H15N2O	[M+H]
+	
227.1179,	found	227.1180.	
5,9b-Dimethyl-3,3a,5,9b-tetrahydro-1H-cyclopenta[c]	
quinoline-1,4(2H)-dione	 (24).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-
(methyl(phenyl)amino)-2-oxoacetate	 (11)	 (77.8	 mg,	 0.24	
mmol)	 and	 2-methyl-2-cyclopenten-1-one	 (34.6	mg,	 35.3	mL,	
0.36	 mmol)	 and	 eluting	 with	 1:3	 hexanes/Et2O	 to	 give	 3,4-
dihydroquinolin-2-one	24	 (21	mg,	38%)	as	a	pale	yellow	solid:	
Rf	 0.24	 (3:5	 hexanes/Et2O);	mp	92–94	 ˚C;	
1
H	NMR	 (400	MHz,	
CDCl3)	δ	(ppm)	7.31	(td,	J	=	8.1,	1.6	Hz,	1H),	7.27–7.22	(m,	1H),	
7.09–7.02	 (comp,	2H),	3.43	 (s,	3H),	2.94	 (dd,	 J	 =	12.1,	6.7	Hz,	
1H),	2.44–2.21	(comp,	3H),	1.80–1.63	(m,	1H),	1.31	(s,	3H);	
13
C	
NMR	 (100	 MHz,	 CDCl3)	 δ	 (ppm)	 216.0,	 169.5,	 138.7,	 128.9,	
127.4,	123.8,	122.4,	115.3,	51.9,	50.1,	50.1,	35.3,	29.7,	23.0;	IR	
(film,	 νmax/cm
-1
)	 2923,	 1738,	 1666,	 1597,	 1453,	 1362;	 HRMS	
(ESI
+
)	 m/z	 calcd.	 for	 C14H16NO2	 [M+H]
+	
230.1176,	 found	
230.1172.	
1-Methyl-4-(pyridin-2-yl)-3,4-dihydroquinolin-2(1H)-one	
(26).	 Prepared	 according	 to	 general	 procedure	 B	 using	 1,3-
dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-oxoacetate	
(11)	 (77.8	mg,	 0.24	mmol)	 and	2-vinylpyridine	 (37.9	mg,	38.8	
mL,	 0.36	mmol).	 Brine	 (50	mL)	 was	 used	 in	 place	 of	 sat.	 aq.	
(NH4Cl)	in	the	work	up	and	the	column	was	eluted	with	Et2O	to	
give	3,4-dihydro-1H-quinolin-2-one	26	 (25	mg,	44%)	as	a	pale	
yellow	gum:	Rf	0.26	(Et2O);	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	
8.60–8.57	(m,	1H),	7.59	(app	td,	J	=	7.7,	2.1	Hz,	1H),	7.30	(ddd,	
J	=	8.5,	6.3,	2.7	Hz,	1H),	7.15	(dd,	J	=	7.7,	4.4	Hz,	1H),	7.08–6.96	
(comp,	4H),	4.37	(app	t,	J	=	6.5	Hz,	1H),	3.37	(s,	3H),	3.26	(dd,	J	
=	16.0,	6.5	Hz,	1H),	2.96	(dd,	J	=	16.0,	6.5	Hz,	1H);	
13
C	NMR	(100	
MHz,	CDCl3)	δ	 (ppm)	169.5,	160.7,	150.0,	140.5,	136.9,	128.4,	
128.2,	127.7,	123.1,	122.2	(2C),	115.1,	43.7,	37.2,	29.6;	IR	(film,	
νmax/cm
-1
)	 2923,	 1670,	 1600,	 1590,	 1470,	 1366,	 1129,	 1136;	
HRMS	(ESI
+
)	m/z	calcd.	for	C15H15N2O	[M+H]
+	
	239.1179,	found	
239.1179.	
N-methyl-N,3,3-triphenylacrylamide	 (27).	 Prepared	
according	 to	general	procedure	B	using	1,3-dioxoisoindolin-2-
yl	 2-(methyl(phenyl)amino)-2-oxoacetate	 (11)	 (77.8	 mg,	 0.24	
mmol)	 and	 1,1-diphenylethylene	 (64.9	 mg,	 63.6	 mL,	 0.36	
mmol)	 and	 eluting	 with	 1:1	 hexanes\Et2O	 to	 give	 N-methyl-
N,3,3-triphenylacrylamide	 27	 (40	 mg,	 53%)	 as	 a	 pale	 yellow	
gum	 which	 solidified	 upon	 standing:	 Rf	 0.18	 (1:1	
hexanes\Et2O);	 mp	 78–80	 ˚C	 (lit.
39
	 81-83	 ˚C);	
1
H	 NMR	 (400	
MHz,	 CDCl3)	 δ	 (ppm)	 7.38–7.28	 (comp,	 4H),	 7.28–7.15	 (comp	
5H),	7.10–6.98	(comp,	4H),	6.87	(d,	J	=	7.5	Hz,	2H),	6.18	(s,	1H),	
3.23	 (s,	 3H);	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	 C22H20NO	 [M+H]
+	
	
314.1539,	 found	 314.1542.	 All	 data	 were	 in	 agreement	 with	
those	reported	in	the	literature.
39
	
Methyl-1,4-dimethyl-2-oxo-6-(trifluoromethyl)-1,2,3,4-
tetrahydroquinoline-4-carboxylate	 (28).	 Prepared	 according	
to	 general	 procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-
(methyl(4-(trifluoromethyl)phenyl)amino)-2-oxoacetate	 (94.1	
mg,	0.24	mmol)	and	methyl	methacrylate	 (13)	 (36.0	mg,	38.5	
mL,	0.36	mmol)	and	eluting	with	2:3	hexanes/Et2O	to	give	3,4-
dihydroquinolin-2-one	 28	 (57	 mg,	 80%)	 as	 a	 colorless	 oil:	 Rf	
0.19	 (2:3	 hexanes/Et2O);	
1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	 (ppm)	
7.61–7.53	(comp,	2H),	7.08	(d,	J	=	8.5	Hz,	1H),	3.68	(s,	3H),	3.37	
(s,	3H),	3.17	(d,	J	=	16.1	Hz,	1H),	2.57	(d,	J	=	16.1	Hz,	1H),	1.64	
(s,	 3H);	
13
C	 NMR	 (100	 MHz,	 CDCl3)	 δ	 	(ppm)	 173.7,	 168.2,	
142.8,	128.6,	126.1	 (q,	 JC-F	 =	3.6	Hz),	125.4	 (q,	 JC-F	 =	33.2	Hz),	
124.1	 (q,	 JC-F	 =	271.0	Hz),	123.4	 (q,	 JC-F	 =	3.6	Hz),	115.4,	53.1,	
44.5,	 41.4,	 29.8,	 23.3;	 IR	 (film,	 νmax/cm
-1
)	 2956,	 1731,	 1686,	
1617,	 1333,	 1275,	 1115,	 1087;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C14H14F3NNaO3	[M+Na]
+	
324.0818,	found	324.0804.	
Methyl	 6-fluoro-1,4-dimethyl-2-oxo-1,2,3,4-tetrahydro	
quinoline-4-carboxylate	 (29).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-((4-
fluorophenyl)(methyl)amino)-2-oxoacetate	 (82.1	 mg,	 0.24	
mmol)	and	methyl	methacrylate	 (13)	 (35.3	mg,	31.6	mL,	0.36	
mmol)	 and	 eluting	 with	 3:7	 hexanes/Et2O	 to	 give	 3,4-
dihydroquinolin-2-one	29	 (47	mg,	78%)	as	a	pale	yellow	solid:	
Rf	0.14	(3:7	hexanes/Et2O);	mp	102–104	˚C;	
1
H	NMR	(400	MHz,	
CDCl3)	δ	(ppm)	7.06–6.98	(comp,	2H),	6.95	(dd,	J	=	8.8,	4.8	Hz,	
1H),	3.70	(s,	3H),	3.34	(s,	3H),	3.13	(d,	J	=	16.2	Hz,	1H),	2.54	(d,	J	
=	16.2	Hz,	1H),	1.59	(s,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	(ppm)	
173.9,	167.9,	158.9	(d,	JC-F	=	243.0	Hz),	136.2	(d,	JC-F	=	2.7	Hz),	
130.1	 (d,	 JC-F	=	7.1	Hz),	116.5	 (d,	 JC-F	=	8.1	Hz),	115.1	 (d,	 JC-F	=	
22.4	Hz),	113.5	(d,	JC-F	=	24.2	Hz),	53.1,	44.6,	41.5,	29.9,	23.4;	IR	
(film,	 νmax/cm
-1
)	 2953,	 1720,	 1670,	 1503,	 1432,	 1354,	 1267,	
1150,	1105;	HRMS	(ESI
+
)	m/z	calcd.	for	C13H14FNNaO3	[M+Na]
+	
	
274.0850,	found	274.0853.	
Methyl-6-chloro-1,4-dimethyl-2-oxo-1,2,3,4-tetrahydro	
quinoline-4-carboxylate	 (30).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl-2-((4-
chlorophenyl)(methyl)	 amino)-2-oxoacetate	 (86.1	 mg,	 0.24	
mmol)	and	methyl	methacrylate	 (13)	 (36.0	mg,	38.5	mL,	0.36	
mmol)	 and	 eluting	 with	 2:3	 hexanes/Et2O	 to	 give	 3,4-
dihydroquinolin-2-one	 30	 (47	 mg,	 73%)	 as	 a	 colorless	 oil:	 Rf	
0.14	 (2:3	 hexanes/Et2O);	
1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	 (ppm)	
7.28–7.24	(comp,	2H),	6.91	(d,	J	=	9.3	Hz,	1H),	3.67	(s,	3H),	3.31	
(s,	3H),	3.10	(d,	J	=	16.0	Hz,	1H),	2.52	(d,	J	=	16.0	Hz,	1H),	1.58	
(s,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	(ppm)	173.8,	167.9,	138.5,	
129.7,	128.7,	128.6,	126.3,	116.5,	53.1,	44.5,	41.4,	29.7,	23.3;	
IR	(film,	νmax/cm
-1
)	2953,	1729,	1677,	1493,	1411,	1354,	1266,	
1246,	1197,	1100;	HRMS	(ESI
+
)	m/z	calcd.	for	C13H14
35
ClNNaO3	
[M+Na]
+
	290.0554,	found	290.0552.	
Methyl	1,4,6-trimethyl-2-oxo-1,2,3,4-tetrahydroquinoline-
4-carboxylate	(31).	Prepared	according	to	general	procedure	B	
using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(p-tolyl)amino)-2-
oxoacetate	 (81.2	 mg,	 0.24	 mmol)	 and	 methyl	 methacrylate	
(13)	 (35.3	 mg,	 31.6	 mL,	 0.36	 mmol)	 and	 eluting	 with	 2:3	
hexanes/Et2O	 to	 give	 3,4-dihydroquinolin-2-one	 31	 (34	 mg,	
57%)	as	a	yellow	solid:	Rf	0.20	(2:3	hexanes/EtOAc);	mp	61–63	
˚C;	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	7.10	(d,	J	=	8.3	Hz,	1H),	
7.07	(s,	1H),	6.89	(d,	J	=	8.3	Hz,	1H),	3.68	(s,	3H),	3.33	(s,	3H),	
3.11	(d,	J	=	15.9	Hz,	1H),	2.53	(d,	J	=	15.9	Hz,	1H),	2.32	(s,	3H),	
1.57	(s,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	 (ppm)	174.5,	168.2,	
137.4,	132.9,	129.1,	127.9,	126.6,	115.2,	52.9,	44.6,	41.8,	29.6,	
23.4,	 20.9;	 IR	 (film,	 νmax/cm
-1
)	 2955,	 2922,	 1726,	 1674,	 1505,	
1471,	 1359,	 1268,	 1140,	 1105;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C14H17NNaO3	[M+Na]
+	
	270.1101,	found	270.1098.	
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Methyl-6-methoxy-1,4-dimethyl-2-oxo-1,2,3,4-tetrahydro	
quinoline-4-carboxylate	 (32).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl-2-((4-
methoxyphenyl)(methyl)amino)-2-oxoacetate	 (85.0	 mg,	 0.24	
mmol)	and	methyl	methacrylate	 (13)	 (36.0	mg,	38.5	mL,	0.36	
mmol)	and	eluting	with	2:3	hexanes/Et2O	to	give	3,4-dihydro-
1H-quinolin-2-one	32	 (24	mg,	 38%)	 as	 a	 pale	 yellow	 solid:	Rf	
0.40	 (1:9	 hexanes/Et2O);	 mp	 97–99	 ˚C;	
1
H	 NMR	 (400	 MHz,	
CDCl3)	d	(ppm)	6.92	(d,	J	=	8.6	Hz,	1H),	6.89–6.78	(comp,	2H),	
3.80	(s,	3H),	3.68	(s,	3H),	3.33	(s,	3H),	3.10	(d,	J	=	15.9	Hz,	1H),	
2.53	 (d,	 J	 =	 15.9	 Hz,	 1H),	 1.57	 (s,	 3H);	
13
C	 NMR	 (100	 MHz,	
CDCl3)	d	(ppm)	174.3,	168.0,	155.7,	133.5,	129.6,	116.2,	112.8,	
112.7,	 55.7,	 52.9,	 44.8,	 41.7,	 29.8,	 23.4;	 IR	 (film,	 νmax/cm
-1
)	
2953,	 1728,	 1668,	 1505,	 1430,	 1295,	 1230;	 HRMS	 (ESI
+
)	m/z	
calcd.	for	C14H17NNaO4	[M+Na]
+
	286.1050,	found	286.1043.	
Methyl	1,4,7-trimethyl-2-oxo-1,2,3,4-tetrahydroquinoline-
4-carboxylate	(33).	Prepared	according	to	general	procedure	B	
using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(m-tolyl)amino)-2-
oxoacetate	 (81.2	 mg,	 0.24	 mmol)	 and	 methyl	 methacrylate	
(13)	 (35.3	 mg,	 31.6	 mL,	 0.36	 mmol)	 and	 eluting	 with	 1:1	
hexanes/Et2O	 to	 give	 3,4-dihydroquinolin-2-one	 33	 (39	 mg,	
66%)	as	a	yellow	solid:	Rf	0.24	(1:1	hexanes/Et2O);	mp	112–114	
˚C;	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	7.17	(d,	J	=	7.7	Hz,	1H),	
6.90	(d,	J	=	7.7	Hz,	1H),	6.82	(s,	1H),	3.67	(s,	3H),	3.35	(s,	3H),	
3.11	(d,	J	=	16.0	Hz,	1H),	2.53	(d,	J	=	16.0	Hz,	1H),	2.36	(s,	3H),	
1.57	(s,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	 (ppm)	174.6,	168.5,	
139.7,	138.7,	125.9,	125.2,	124.0,	116.1,	52.8,	44.3,	41.8,	29.6,	
23.5,	 21.5;	 IR	 (film,	 νmax/cm
-1
)	 2918,	 1722,	 1671,	 1607,	 1408,	
1348,	1269,	1248,	1196,	1137,	1101;	HRMS	(ESI
+
)	m/z	calcd.	for	
C14H17NNaO3	[M+Na]
+	
	270.1101,	found	270.1103.	
Methyl	 8-fluoro-1,4-dimethyl-2-oxo-1,2,3,4-tetrahydro	
quinoline-4-carboxylate	 (35).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-((2-
fluorophenyl)(methyl)amino)-2-oxoacetate	 (82.1	 mg,	 0.24	
mmol)	and	methyl	methacrylate	 (13)	 (35.3	mg,	31.6	mL,	0.36	
mmol)	 and	 eluting	 with	 3:2	 hexanes/Et2O	 to	 afford	 crude	
material	 which	 was	 repurified	 by	 silica	 gel	 flash	 column	
chromatography,	 eluting	with	 1:1	 hexanes/EtOAc	 to	 give	 3,4-
dihydroquinolin-2-one	35	 (25	mg,	41%)	as	a	colorless	solid:	Rf	
0.29	 (7:3	 hexanes/Et2O);	 mp	 61–63	 ˚C;	
1
H	 NMR	 (400	 MHz,	
CDCl3)	δ	(ppm)	7.10–7.01	(comp,	3H),	3.70	(s,	3H),	3.41	(d,	J	=	
6.6	Hz,	3H),	3.07	(d,	J	=	15.7	Hz,	1H),	2.53	(d,	J	=	15.7	Hz,	1H),	
1.58	(s,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	 (ppm)	173.9,	169.1,	
152.3	(d,	JC-F	=	247.8	Hz),	133.0	(d,	JC-F	=	1.5	Hz),	128.9	(d,	JC-F	=	
8.1	Hz),	124.7	(d,	JC-F	=	8.4	Hz),	121.2	(d,	JC-F	=	3.0	Hz),	116.9	(d,	
JC-F	=	22.0	Hz),	53.0,	45.2,	42.1,	33.7	(d,	JC-F	=	11.7	Hz),	23.0;	IR	
(film,	 νmax/cm
-1
)	 2954,	 1732,	 1685,	 1479,	 1354,	 1243,	 1101;	
HRMS	 (ESI
+
)	m/z	 calcd.	 for	 C13H14FNNaO3	 [M+Na]
+	
	 274.0850,	
found	274.0845.	
Methyl-1-benzyl-4-methyl-2-oxo-1,2,3,4-tetrahydro	
quinoline-4-carboxylate	 (36).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-
(benzyl(phenyl)amino)-2-oxoacetate	(96.1	mg,	0.24	mmol)	and	
methyl	methacrylate	 (13)	 (36.0	mg,	38.5	mL,	0.36	mmol)	and	
eluting	 with	 2:3	 hexanes/Et2O	 to	 give	 3,4-dihydroquinolin-2-
one	36	(40	mg,	54%)	as	a	yellow	oil:	Rf	0.37	(2:3	hexanes/Et2O);	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	7.33–7.26	(comp,	3H),	7.24–
7.19	 (comp,	 3H),	 7.19–7.13	 (m,	 1H),	 7.04	 (t,	 J	 =	 7.5	 Hz,	 1H),	
6.92	 (d,	 J	 =	8.1	Hz,	1H),	5.27	 (d,	 J	 =	16.2	Hz,	1H),	5.13	 (d,	 J	 =	
16.2	Hz,	1H),	3.68	(s,	3H),	3.25	(d,	J	=	15.8	Hz,	1H),	2.71	(d,	J	=	
15.8	Hz,	1H),	1.65	(s,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	 (ppm)	
174.3,	 168.5,	 138.9,	 136.9,	 128.8,	 128.7,	 128.2,	 127.2,	 126.7,	
126.2,	 123.5,	 116.1,	 52.9,	 45.8,	 44.7,	 41.8,	 23.5;	 IR	 (film,	
νmax/cm
-1
)	 2952,	 1728,	 1676,	 1599,	 1496,	 1454,	 1375,	 1268,	
1103;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	 C19H19NNaO3	 [M+Na]
+	
	
332.1257,	found	332.1249.	
Methyl-1-allyl-4-methyl-2-oxo-1,2,3,4-tetrahydro	
quinoline-4-carboxylate	 (37).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl-2-
(allyl(phenyl)amino)-2-oxoacetate	 (84.1	 mg,	 0.24	 mmol)	 and	
methyl	methacrylate	 (13)	 (36.0	mg,	38.5	mL,	0.36	mmol)	and	
eluting	 with	 2:3	 hexanes/Et2O	 to	 give	 3,4-dihydroquinolin-2-
one	 37	 (28	 mg,	 45%)	 as	 a	 white	 solid:	 Rf	 0.32	 (2:3	
hexanes/Et2O);	 mp	 81–83	 ˚C;	
1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	
(ppm)	7.31–7.23	(comp,	2H),	7.07	(td,	J	=	8.2,	1.1	Hz,	1H),	7.00	
(dd,	J	=	8.2,	1.0	Hz,	1H),	5.85	(ddt,	 J	=	17.2,	10.4,	4.8	Hz,	1H),	
5.18	(ddd,	J	=	10.4,	2.8,	1.8	Hz,	1H),	5.14	(ddd,	J	=	17.2,	2.8,	1.8	
Hz,	1H),	4.60	(ddt,	J	=	16.8,	4.8,	1.8	Hz,	1H),	4.55	(ddt,	J	=	16.8,	
4.8,	1.8	Hz,	1H),	3.68	(s,	3H),	3.15	(d,	J	=	15.8	Hz,	1H),	2.61	(d,	J	
=	15.8	Hz,	1H),	1.61	(s,	3H);	
13
C	NMR	(100	MHz,	CDCl3)	δ	(ppm)	
174.3,	 168.0,	 139.0,	 132.5,	 128.7,	 128.2,	 126.1,	 123.5,	 116.7,	
116.1,	 52.9,	 44.9,	 44.8,	 41.8,	 23.4;	 IR	 (film,	 νmax/cm
-1
)	 2952,	
1728,	 1676,	 1599,	 1458,	 1373,	 1225,	 1103;	 HRMS	 (ESI
+
)	m/z	
calcd.	for	C15H17NNaO3	[M+Na]
+	
282.1101,	found	282.1092.	
1'-Methyl-6'-(trifluoromethyl)-4,5-dihydro-1'H,2H-
spiro[furan-3,4'-quinoline]-2,2'(3'H)-dione	 (39).	 Prepared	
according	 to	general	procedure	B	using	1,3-dioxoisoindolin-2-
yl	 2-(methyl(4-(trifluoro	 methyl)phenyl)amino)-2-oxoacetate	
(94.1	mg,	0.24	mmol)	and	α-methylene-γ-butyrolactone	 (35.3	
mg,	31.6	mL,	0.36	mmol)	and	eluting	with	Et2O	to	give	 spiro-
3,4-dihydroquinolin-2-one	39	(51	mg,	71%)	as	a	white	solid:	Rf	
0.26	(Et2O);	mp	135–137	˚C;
	1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	
7.63	(dd,	J	=	8.6,	1.5	Hz,	1H),	7.31	(d,	J	=	1.5	Hz,	1H),	7.17	(d,	J	=	
8.6	Hz,	1H),	4.48	(ddd,	J	=	9.6,	7.9,	4.6	Hz,	1H),	4.36	(dt,	J	=	9.6,	
7.4	Hz,	1H),	3.43	(s,	3H),	3.10	(d,	J	=	16.1	Hz,	1H),	2.76	(d,	J	=	
16.1	Hz,	1H),	2.50	(dt,	J	=	13.1,	7.9	Hz,	1H),	2.34	(ddd,	J	=	13.1,	
7.4,	 4.6	 Hz,	 1H);	
13
C	 NMR	 (100	 MHz,	 CDCl3)	 δ	 (ppm)	 177.0,	
167.0,	142.3,	126.6	(q,	JC-F	=	3.7	Hz),	126.4,	125.8	(q,	JC-F	=	33.5	
Hz),	 123.8	 (q,	 JC-F	 =	 271.5	 Hz),	 122.6	 (q,	 JC-F	 =	 3.7	 Hz),	 116.0,	
65.2,	 46.0,	 39.1,	 35.5,	 30.0;	 IR	 (film,	 νmax/cm
-1
)	 2922,	 1768,	
1683,	1618,	1337,	1281,	1168,	1140,	1115,	1089;	HRMS	(ESI
+
)	
m/z	 calcd.	 for	 C14H12F3NNaO3	 [M+Na]
+
	 322.0661,	 found	
322.0664.	
6'-Fluoro-1'-methyl-4,5-dihydro-1'H,2H-spiro[furan-3,4'-
quinoline]-2,2'(3'H)-dione	(40).	Prepared	according	to	general	
procedure	 B	 using	 oxamide	 1,3-dioxoisoindolin-2-yl	 2-((4-
fluorophenyl)(methyl)amino)-2-oxoacetate	 (82.1	 mg,	 0.24	
mmol)	 and	 α-methylene-γ-butyrolactone	 (35.3	 mg,	 31.6	 mL,	
0.36	mmol)	and	eluting	with	Et2O	to	give	spiro-3,4-dihydro-1H-
quinolin-2-one	40	(37	mg,	62%)	as	a	white	solid:	Rf	0.18	(Et2O);	
mp	120–122	˚C;
	1
H	NMR	(400	MHz,	CDCl3)	δ	 (ppm)	7.09–7.00	
(comp,	2H),	6.83	(dd,	J	=	8.5,	0.5	Hz,	1H),	4.45	(ddd,	J	=	9.5,	8.0,	
4.5	 Hz,	 1H),	 4.34	 (ddd,	 J	 =	 9.5,	 8.0,	 7.1	 Hz,	 1H),	 3.38	 (s,	 3H),	
3.06	(d,	J	=	16.0	Hz,	1H),	2.69	(d,	J	=	16.0	Hz,	1H),	2.47	(dt,	J	=	
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13.0,	8.0	Hz,	1H),	2.30	(ddd,	J	=	13.0,	7.1,	4.5	Hz,	1H);	
13
C	NMR	
(100	MHz,	 CDCl3)	 δ	 (ppm)	177.2,	 166.8,	 158.8	 (d,	 JC-F	 =	 245.1	
Hz),	135.8	(d,	JC-F	=	2.7	Hz),	127.6	(d,	JC-F	=	7.3	Hz),	117.2	(d,	JC-F	
=	7.9	Hz),	115.6	(d,	JC-F	=	22.3	Hz),	113.0	(d,	JC-F	=	24.5	Hz),	65.2,	
46.0,	 39.1,	 35.5,	 30.0;	 IR	 (film,	 νmax/cm
-1
)	 2922,	 1766,	 1672,	
1504,	 1364,	 1185,	 1122,	 1023;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C13H12FNNaO3	[M+Na]
+
	272.0693,	found	272.0687.	
6'-Chloro-1'-methyl-4,5-dihydro-1'H,2H-spiro[furan-3,4'-
quinoline]-2,2'(3'H)-dione	(41).	Prepared	according	to	general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl-2-((4-
chlorophenyl)(methyl)amino)-2-oxoacetate	 (86.1	 mg,	 0.24	
mmol)	 and	 α-methylene-γ-butyrolactone	 (35.3	 mg,	 31.6	 mL,	
0.36	mmol)	 and	 eluting	 with	 1:3	 hexanes/Et2O	 to	 give	 spiro-
3,4-dihydroquinolin-2-one	41	(34	mg,	53%)	as	a	yellow	solid:	Rf	
0.47	(Et2O);	mp	142–144	˚C;
	1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	
7.32	(dd,	J	=	8.7,	2.3	Hz,	1H),	7.07	(d,	J	=	2.3	Hz,	1H),	7.00	(d,	J	=	
8.7	Hz,	1H),	4.46	(ddd,	J	=	9.4,	8.0,	4.3	Hz,	1H),	4.35	(ddd,	 J	=	
9.4,	8.0,	7.1	Hz,	1H),	3.38	(s,	3H),	3.07	(d,	J	=	16.0	Hz,	1H),	2.70	
(d,	J	=	16.0	Hz,	1H),	2.47	(dt,	J	=	13.0,	8.0	Hz,	1H),	2.30	(ddd,	J	=	
13.0,	 7.1,	 4.3	 Hz,	 1H);	
13
C	 NMR	 (100	 MHz,	 CDCl3)	 δ	 (ppm)	
177.1,	 166.9,	 138.2,	 129.2,	 129.1,	 127.5,	 125.6,	 117.1,	 65.2,	
46.0,	 39.2,	 35.6,	 29.9;	 IR	 (film,	 νmax/cm
-1
)	 1767,	 1674,	 1597,	
1495,	 1413,	 1356,	 1170,	 1023;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C13H12
35
ClNNaO3	[M+Na]
+	
	288.0398,	found	288.0401.	
1'-Methyl-4,5-dihydro-1'H,2H-spiro[furan-3,4'-quinoline]-
2,2'(3'H)-dione	(42).	Prepared	according	to	general	procedure	
B	 using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-
oxoacetate	 (7)	 (77.8	 mg,	 0.24	 mmol)	 and	 α-methylene-γ-
butyrolactone	(35.3	mg,	31.6	mL,	0.36	mmol)	and	eluting	with	
Et2O	 to	 give	 spiro-3,4-dihydroquinolin-2-one	42	 (37	mg,	 67%)	
as	a	pale	yellow	solid:	Rf	0.33	(Et2O);	mp	107–109	˚C;	
1
H	NMR	
(400	MHz,	CDCl3)	δ	(ppm)	7.36	(dd,	J	=	7.2,	1.6	Hz,	1H),	7.15–
7.05	(comp,	3H),	4.45	(ddd,	J	=	9.1,	8.4,	3.8	Hz,	1H),	4.32	(ddd,	J	
=	 9.1,	 8.4,	 6.9	Hz,	 1H),	 3.41	 (s,	 3H),	 3.12	 (d,	 J	 =	 16.0	Hz,	 1H),	
2.69	(d,	J	=	16.0	Hz,	1H),	2.46	(app	dt,	J	=	13.0,	8.4	Hz,	1H),	2.30	
(ddd,	 J	 =	 13.0,	 8.4,	 6.9	Hz,	 1H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	
(ppm)	 177.8,	 167.4,	 139.5,	 129.3,	 125.8,	 125.4,	 123.8,	 115.9,	
65.2,	 46.1,	 39.6,	 35.9,	 29.8;	 IR	 (film,	 νmax/cm
-1
)	 2958,	 2923,	
1773,	1665,	1597,	1470,	1361,	1176,	1140,	1023;	HRMS	(ESI
+
)	
m/z	 calcd.	 for	 C13H13NNaO3	 [M+Na]
+	
	 254.0788,	 found	
254.0787.	
5'-Methoxy-1'-methyl-4,5-dihydro-1'H,2H-spiro[furan-
3,4'-quinoline]-2,2'(3'H)-dione	 (43a)	 and	 7'-Methoxy-1'-
methyl-4,5-dihydro-1'H,2H-spiro[furan-3,4'-quinoline]-
2,2'(3'H)-dione	 (43b).	 Prepared	 according	 to	 general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl-2-((3-
methoxyphenyl)(methyl)amino)-2-oxoacetate	 (85.0	 mg,	 0.24	
mmol)	 and	 α-methylene-γ-butyrolactone	 (35.3	 mg,	 31.6	 mL,	
0.36	 mmol)	 and	 eluting	 with	 2:3	 hexanes/Et2O	 to	 give	 an	
inseparable	 mixture	 of	 spiro-3,4-dihydroquinolin-2-ones	 43a	
and	 43b	 (27	mg,	 43%)	 as	 a	 yellow	 oil	 (43a:43b	 1.00:0.56).	Rf	
0.26	 (1:9	 hexanes/Et2O);
	 1
H	 NMR	 (400	 MHz,	 CDCl3)	 δ	 (ppm)	
(43a	major)	 7.29	 (t,	 J	 =	 8.3	Hz,	 1H),	 6.73–6.68	 (m,	2H),	 4.49–
4.33	(m,	2H),	3.82	(s,	3H),	3.37	(s,	3H),	3.01	(d,	J	=	15.7	Hz,	1H),	
2.70	(d,	J	=	15.7	Hz,	1H),	2.46–2.31	(m,	2H);	
1
H	NMR	(400	MHz,	
CDCl3)	δ	(ppm)	(43b	minor)	6.98	(d,	J	=	8.3	Hz,	1H),	6.65–6.57	
(m,	2H),	4.40–4.25	(m,	2H),	3.82	(s,	3H),	3.37	(s,	3H),	3.07	(d,	J	
=	15.9	Hz,	1H),	2.67	(d,	J	=	15.9	Hz,	1H),	2.36–2.22	(m,	2H);	
13
C	
NMR	 (100	 MHz,	 CDCl3)	 δ	 (ppm)	 179.8,	 178.0,	 167.6,	 166.7,	
160.3,	 155.8,	 141.2,	 140.7,	 129.7,	 126.2,	 118.1,	 115.5,	 108.9,	
107.6,	 107.2,	 103.7,	 65.6,	 65.2,	 56.2,	 55.7,	 45.5,	 42.9,	 40.3,	
39.8,	 36.0,	 34.8,	 30.4,	 30.1;	 IR	 (film,	 νmax/cm
-1
)	 2923,	 1766,	
1673,	1595,	1474,	1356,	1259,	1216,	1144,	1026;	HRMS	(ESI
+
)	
m/z	 calcd.	 for	 C14H15NNaO4	 [M+Na]
+
	 284.0893,	 found	
284.0901.	
6'-Chloro-1'-methyl-1-phenyl-1'H-spiro[pyrrolidine-3,4'-
quinoline]-2,2'(3'H)-dione	(44).	Prepared	according	to	general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl-2-((4-
chlorophenyl)(methyl)	 amino)-2-oxoacetate	 (86.1	 mg,	 0.24	
mmol)	 and	 3-methylidene-1-phenylpyrrolidin-2-one
40
	 (48.0	
mg,	 0.36	 mmol)	 and	 eluting	 with	 Et2O	 to	 give	 spiro-3,4-
dihydro-1H-quinolin-2-one	 44	 (41	 mg,	 50%)	 as	 a	 pale	 yellow	
solid:	Rf	0.28	(Et2O);	mp	125–127	˚C;
	1
H	NMR	(400	MHz,	CDCl3)	
δ	(ppm)	7.72	(d,	J	=	7.9	Hz,	2H),	7.44	(dd,	 J	=	7.9,	7.5	Hz,	2H),	
7.29	(dd,	J	=	8.5,	2.3	Hz,	1H),	7.24	(t,	J	=	7.5	Hz,	1H),	7.04	(d,	J	=	
2.3	Hz,	1H),	6.99	(d,	J	=	8.5	Hz,	1H),	3.92–3.86	(comp,	2H),	3.40	
(s,	3H),	3.17	(d,	J	=	16.0	Hz,	1H),	2.71	(d,	J	=	16.0	Hz,	1H)	2.36	
(app	dt,	J	=	12.9,	7.6	Hz,	1H),	2.27–2.19	(m,	1H);	
13
C	NMR	(100	
MHz,	CDCl3)	δ	 (ppm)	173.2,	167.9,	138.8,	138.5,	129.6,	129.2,	
128.9,	 128.6,	 125.6	 (2C),	 120.3,	 116.9,	 48.7,	 45.1,	 39.7,	 32.1,	
29.8;	 IR	 (film,	νmax/cm
-1
)	2924,	1675,	1596,	1494,	1397,	1356,	
1301,	 1228,	 1139;	 HRMS	 (ESI
+
)	m/z	 calcd.	 for	 C19H18
35
ClN2O2	
[M+H]
+
	341.1051,	found	341.1032.	
1'-Methyl-1-phenyl-1'H-spiro[pyrrolidine-3,4'-quinoline]-
2,2'	(3'H)-dione	(45).	Prepared	according	to	general	procedure	
B	 using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-
oxoacetate	 (11)	 (77.8	 mg,	 0.24	 mmol)	 and	 3-methylidene-1-
phenylpyrrolidin-2-one
40
	 (48.0	 mg,	 0.36	 mmol)	 and	 eluting	
with	2:3	hexanes/Et2O	to	give	spiro-3,4-dihydro-1H-quinolin-2-
one	 45	 (37	 mg,	 49%)	 as	 a	 colourless	 oil:	 Rf	 0.18	 (2:3	
hexanes/Et2O);
	 1
H	 NMR	 (400	MHz,	 CDCl3)	 δ	 (ppm)	 7.79–7.70	
(m,	2H),	 7.48–7.39	 (m,	2H),	 7.35–7.29	 (m,	1H),	 7.25–7.19	 (m,	
1H),	 7.10–7.01	 (comp,	 3H),	 3.90–3.84	 (m,	 2H),	 3.42	 (s,	 3H),	
3.21	(d,	J	=	16.0	Hz,	1H),	2.70	(d,	J	=	16.0	Hz,	1H),	2.34	(dt,	J	=	
12.8,	8.0	Hz,	1H),	2.28–2.18	(m,	1H);	
13
C	NMR	(100	MHz,	CDCl3)	
δ	(ppm)	174.0,	168.4,	139.7,	139.0,	129.2,	128.7,	127.8,	125.6,	
125.3,	123.6,	120.1,	115.7,	48.7,	45.1,	40.1,	32.3,	29.7;	IR	(film,	
νmax/cm
-1
)	 2925,	 2247,	 1671,	 1597,	 1497,	 1395,	 1361,	 1300,	
1227;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	 C19H18N2NaO2	 [M+Na]
+
	
329.1260,	found	329.1251.	
1',6'-Dimethyl-1-phenyl-1'H-spiro[pyrrolidine-3,4'-
quinoline]-2,2'(3'H)-dione	(46).	Prepared	according	to	general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(p-
tolyl)amino)-2-oxoacetate	 (81.2	 mg,	 0.24	 mmol)	 and	 3-
methylidene-1-phenylpyrrolidin-2-one
40
	 (48.0	mg,	0.36	mmol)	
and	 eluting	 with	 2:3	 hexanes/Et2O	 to	 give	 spiro-3,4-
dihydroquinolin-2-one	46	 (41	mg,	61%)	as	a	pale	yellow	solid:	
Rf	0.21	(2:3	hexanes/Et2O);	mp	138–140	˚C;
	1
H	NMR	(400	MHz,	
CDCl3)	 δ	 (ppm)	 7.78–7.71	 (m,	 2H),	 7.47–7.41	 (m,	 2H),	 7.25–
7.19	(m,	1H),	7.11	(dd,	J	=	8.3,	1.4	Hz,	1H),	6.96	(d,	J	=	8.3	Hz,	
1H),	6.83		(d,	J	=	1.4	Hz,	1H),	3.88	(dd,	J	=	7.9,	5.6	Hz,	2H),	3.40	
(s,	3H),	3.18	(d,	J	=	15.9	Hz,	1H),	2.68	(d,	J	=	15.9	Hz,	1H),	2.34	
(dt,	J	=	12.7,	7.9	Hz,	1H),	2.27	(s,	3H),	2.20	(dt,	J	=	12.7,	5.6	Hz,	
1H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	 174.1,	 168.2,	 139.1,	
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137.3,	 133.3,	 129.2,	 129.1,	 127.8,	 125.9,	 125.3,	 120.2,	 115.6,	
48.8,	 45.1,	 40.2,	 32.3,	 29.7,	 20.9;	 IR	 (film,	 νmax/cm
-1
)	 2923,	
1670,	1597,	1499,	1396,	1364,	1141;	HRMS	(ESI
+
)	m/z	calcd.	for	
C20H20N2NaO2	[M+Na]
+
	343.1417,	found	343.1400.	
1'-Methyl-6'-(trifluoromethyl)-1'H-spiro[chroman-3,4'-
quinoline]-2',4(3'H)-dione	(47).	Prepared	according	to	general	
procedure	 B	 using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(4-
(trifluoromethyl)phenyl)amino)-2-oxoacetate	 (94.1	 mg,	 0.24	
mmol)	 and	 3-methylenechroman-4-one
41
	 (57.7	 mg,	 0.36	
mmol)	 and	 eluting	 with	 3:2	 hexanes\Et2O	 to	 give	 spiro-3,4-
dihydro-1H-quinolin-2-one	47	(52	mg,	60%)	as	a	colorless	gum:	
Rf	0.19	(Et2O);	
1
H	NMR	(400	MHz,	CDCl3)	d	(ppm)	7.97	(dd,	J	=	
8.0,	 1.5	 Hz,	 1H),	 7.63–7.54	 (comp,	 2H),	 7.50–7.47	 (m,	 1H),	
7.18–7.19	(comp,	2H),	7.04	(d,	J	=	8.4	Hz,	1H),	4.56	(d,	J	=	11.8	
Hz,	1H),	4.39	(d,	J	=	11.8	Hz,	1H),	3.44	(s,	3H),	3.04	(d,	J	=	16.3	
Hz,	1H),	2.79	(d,	J	=	16.3	Hz,	1H);	
13
C	NMR	(100	MHz,	CDCl3)	d	
(ppm)	191.6,	167.0,	161.1,	137.1,	128.3,	126.7	(q,	JC-F	=	3.7	Hz),	
125.5	(q,	JC-F	=	33.3	Hz),	124.4,	124.2	(q,	JC-F	=	3.8	Hz),	123.9	(q,	
JC-F	 =	 271.9	 Hz),	 122.7,	 119.9,	 118.2,	 115.8,	 72.7,	 47.5,	 35.6,	
29.9;	 IR	 (film,	νmax/cm
-1
)	2925,	1683,	1605,	1478,	1465,	1325,	
1284,	 1117,	 1089,	 1050;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C19H15F3NO3	[M+H]
+
	362.0999,	found	362.1005.	
(4'R,8R,9S,13S,14S)-6'-chloro-3-methoxy-1',13-dimethyl-
7,8,9,11,12,13,14,15-octahydro-1'H-spiro[cyclopenta[a]	
phenanthrene-16,4'-quinoline]-2',17	 (3'H,6H)-dione	 (48).	
Prepared	 according	 to	 general	 procedure	 B	 using	 1,3-
dioxoisoindolin-2-yl-2-((4-chlorophenyl)(methyl)amino)-2-
oxoacet	 ate	 (86.1	 mg,	 0.24	 mmol)	 and	 (8R,9S,13S,14S)-3-
methoxy-13-methyl-16-methylene-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one
42
	 (107	
mg,	 0.36	 mmol)	 and	 eluting	 with	 19:1	 CH2Cl2/Et2O	 to	 afford	
crude	material	which	was	repurified	by	silica	gel	 flash	column	
chromatography,	eluting	with	3:7	hexanes/Et2O	to	give	 spiro-
3,4-dihydro-1H-quinolin-2-one	48	 (25	mg,	 22%)	 as	 a	 colorless	
solid:	Rf	0.23	(3:7	hexanes/Et2O);	[α]D
22
	+1.2	(c	1.25,	CHCl3);	mp	
185–187	˚C;	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	7.27	(dd	J	=	8.7,	
2.4	Hz,	 1H),	 7.20	 (d,	 J	 =	 8.6	Hz,	 1H),	 6.98	 (d,	 J	 =	 8.7	Hz,	 1H),	
6.75–6.71	(comp,	2H),	6.63	(d,	J	=	2.7	Hz,	1H),	3.78	(s,	3H),	3.39	
(s,	3H),	3.04	(d,	J	=15.6	Hz,	1H),	2.90–2.83	(comp,	2H),	2.57	(d,	
J	 =	 15.6	 Hz,	 1H),	 2.51–2.43	 (m,	 1H),	 2.41–2.31	 (m,	 1H),	 2.10	
(dd,	 J	 =	12.6,	5.3	Hz,	1H),	1.96	 (app	 t,	 J	 =	12.6	Hz,	1H),	1.90–
1.82	(m,	1H),	1.80–1.54	(comp,	5H),	1.43–1.30	(m,	1H),	1.05	(s,	
3H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	 221.0,	 168.0,	 157.8,	
138.7,	 137.7,	 132.3,	 131.8,	 128.4,	 128.1,	 126.4,	 126.3,	 116.9,	
114.0,	111.7,	55.3,	52.2,	49.7,	46.9,	44.0,	42.5,	37.8,	36.6,	31.7,	
29.9,	 29.6,	 26.7,	 25.8,	 15.4;	 IR	 (film,	 νmax/cm
-1
)	 2928,	 1738,	
1676,	1608,	1493,	1410,	1356,	1255,	1138,	1044;	HRMS	(ESI
+
)	
m/z	 calcd.	 for	 C28H31
35
ClNO3	 [M+H]
+
	 464.1987,	 found	
464.1966.	
Methyl	 1-methyl-2-oxo-1,2-dihydroquinoline-4-
carboxylate	 (56).	Prepared	 according	 to	 general	 procedure	 B	
using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(phenyl)amino)-2-
oxoacetate	 (11)	 (77.8	 mg,	 0.24	 mmol)	 and	 methyl	 a-
chloroacrylate	(43.4	mg,	36.5	mL,	0.36	mmol)	and	eluting	with	
1:1	 hexanes/EtOAc	 to	 give	 3,4-dihydro-1H-quinolin-2-one	 56	
(31	 mg,	 59%)	 as	 a	 pale	 yellow	 solid:	 Rf	 0.21	 (1:1	
hexanes/EtOAc);	 mp	 111–113	 ˚C	 [lit.
43
	 117-119	 ˚C	
(hexane/ether)];	
1
H	NMR	(400	MHz,	CDCl3)	δ	(ppm)	8.35	(dd,	J	
=	8.1,	1.2	Hz,	1H),	7.66–7.58	 (m,	1H),	7.42	 (d,	J	=	8.5	Hz,	1H),	
7.30	(t,	J	=	8.1	Hz,	1H),	7.22	(s,	1H),	3.99	(s,	1H),	3.75	(s,	3H);	all	
1
H	NMR	data	were	 consistent	with	 those	previously	 reported	
in	 the	 literature;
43
	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	 166.0,	
161.5,	 140.5,	 138.6,	 131.3,	 127.4,	 124.6,	 122.9,	 117.6,	 114.7,	
53.0,	 30.0;	 IR	 (film,	 νmax/cm
-1
)	 2923,	 1727,	 1660,	 1589,	 1426,	
1246,	 1194,	 1072,	 1017;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	
C12H11NNaO3	[M+Na]
+
	240.0631,	found	240.0627.	
Methyl	 1,6-dimethyl-2-oxo-1,2-dihydroquinoline-4-
carboxylate	 (57).	Prepared	 according	 to	 general	 procedure	 B	
using	 1,3-dioxoisoindolin-2-yl	 2-(methyl(p-tolyl)amino)-2-
oxoacetate	(81.2	mg,	0.24	mmol)	and	methyl	a-chloroacrylate	
(43.4	mg,	 36.5	mL,	 0.36	mmol)	 and	 eluting	 with	 1:1	 Et2O	 to	
give	 3,4-dihydro-1H-quinolin-2-one	 57	 (22	 mg,	 40%)	 as	 a	
yellow	solid:	Rf	0.24	(Et2O);	mp	152–154	˚C;	
1
H	NMR	(400	MHz,	
CDCl3)	δ	(ppm)	8.10	(s,	1H),	7.42	(br	d,	J	=	8.7	Hz,	1H),	7.29	(d,	J	
=	 8.7	Hz,	 1H),	 7.17	 (s,	 1H),	 3.98	 (s,	 3H),	 3.71	 (s,	 3H),	 2.42	 (s,	
3H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	 166.1,	 161.2,	 138.5,	
138.4,	 132.6,	 132.5,	 126.9,	 124.3,	 117.5,	 114.5,	 53.0,	 29.9,	
21.0;	 IR	 (film,	νmax/cm
-1
)	2921,	1717,	1651,	1580,	1441,	1238,	
1157,	 1074,	 1037;	 HRMS	 (ESI
+
)	 m/z	 calcd.	 for	 C13H13NNaO3	
[M+Na]
+	
	254.0788,	found	254.0782.	
1,6-Dimethyl-2-oxo-1,2-dihydroquinoline-4-carbonitrile	
(58).	 Prepared	 according	 to	 general	 procedure	 B	 using	 1,3-
dioxoisoindolin-2-yl	 2-(methyl(p-tolyl)amino)-2-oxoacetate	
(81.2	mg,	0.24	mmol)	and	2-chloroacrylonitrile	(31.5	mg,	28.7	
mL,	0.36	mmol)	and	eluting	with	Et2O	to	give	3,4-dihydro-1H-
quinolin-2-one	58	 (12	mg,	25%)	as	a	pale	brown	solid:	Rf	0.38	
(Et2O);	mp	191–193	˚C	[lit.
44
	197-198	˚C	(EtOH)];	
1
H	NMR	(400	
MHz,	CDCl3)	δ	 (ppm)	7.71	 (br	s,	1H),	7.52	 (dd,	 J	=	8.7,	1.6	Hz,	
1H),	7.33	(d,	J	=		8.7	Hz,	1H),	7.13	(s,	1H),	3.72	(s,	3H),	2.48	(s,	
3H);	
13
C	NMR	 (100	MHz,	 CDCl3)	 δ	 (ppm)	
13
C	NMR	 (100	MHz,	
CDCl3)	δ	(ppm)	160.0,	138.1,	134.1,	133.6,	128.7,	126.5,	122.5,	
117.3,	114.9,	114.7,	30.1,	20.8;	IR	(film,	νmax/cm
-1
)	3036,	2922,	
2238,	1741,	1651,	1590,	1562,	1452,	1415,	1316,	1072;	HRMS	
(ESI
+
)	m/z	 calcd.	 for	 C12H10N2NaO	 [M+Na]
+	
	 221.0685,	 found	
221.0675.	
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